US20060252077A1 - Stabilizing a nucleic acid for nucleic acid sequencing - Google Patents

Stabilizing a nucleic acid for nucleic acid sequencing Download PDF

Info

Publication number
US20060252077A1
US20060252077A1 US11/413,381 US41338106A US2006252077A1 US 20060252077 A1 US20060252077 A1 US 20060252077A1 US 41338106 A US41338106 A US 41338106A US 2006252077 A1 US2006252077 A1 US 2006252077A1
Authority
US
United States
Prior art keywords
primer
nucleic acid
template
sequencing
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/413,381
Inventor
Philip Buzby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Standard Biotools Corp
Original Assignee
Helicos BioSciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicos BioSciences Corp filed Critical Helicos BioSciences Corp
Priority to US11/413,381 priority Critical patent/US20060252077A1/en
Publication of US20060252077A1 publication Critical patent/US20060252077A1/en
Assigned to HELICOS BIOSCIENCES CORPORATION reassignment HELICOS BIOSCIENCES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUZBY, PHILIP R.
Assigned to FLUIDIGM CORPORATION reassignment FLUIDIGM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HELICOS BIOSCIENCES CORPORATION
Assigned to PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reassignment PACIFIC BIOSCIENCES OF CALIFORNIA, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to SEQLL, LLC reassignment SEQLL, LLC LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to COMPLETE GENOMICS, INC. reassignment COMPLETE GENOMICS, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Assigned to ILLUMINA, INC. reassignment ILLUMINA, INC. LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: FLUIDIGM CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing

Definitions

  • the invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex attached to a substrate.
  • methods of the invention comprise the use of a dual-anchored primer/target nucleic acid duplex or stabilizing molecule.
  • Cancer is a disease that is rooted in heterogeneous genomic instability. Most cancers develop from a series of genomic changes, some subtle and some significant, that occur in a small subpopulation of cells. Knowledge of the sequence variations that lead to cancer will lead to an understanding of the etiology of the disease, as well as ways to treat and prevent it.
  • An essential first step in understanding genomic duplexity is the ability to perform high-resolution sequencing.
  • nucleic acid sequencing Various approaches to nucleic acid sequencing exist.
  • One conventional way to do bulk sequencing is by chain termination and gel separation, essentially as described by Sanger et al., Proc. Natl. Acad. Sci., 74(12): 5463-67 (1977). That method relies on the generation of a mixed population of nucleic acid fragments representing terminations at each base in a sequence. The fragments are then run on an electrophoretic gel and the sequence is revealed by the order of fragments in the gel.
  • Another conventional bulk sequencing method relies on chemical degradation of nucleic acid fragments. See, Maxam et al., Proc. Natl. Acad. Sci., 74: 560-564 (1977).
  • methods have been developed based upon sequencing by hybridization. See, e.g., Drrnanac, et al., Nature Biotech., 16: 54-58 (1998).
  • the invention generally provides methods and surfaces for nucleic acid sequencing comprising stabilized primer/target nucleic acid duplexes on a surface.
  • Methods of the invention generally contemplate the use of a primer/target nucleic acid duplex in which each of the primer and the template contain a molecule having a binding partner on the substrate.
  • the primer/target is stabilized on the surface by binding of both the primer and the template to the surface.
  • Binding pairs for use in the invention are any molecular pair that can be bound to a surface and attached to a nucleic acid.
  • Some examples of preferred pairs include ligand/receptor, affinity pairs, antigen/antibody, and carbohydrate/lectin.
  • biotin/streptavidin, digoxigenin/anti-digoxigenin, and dinitrophenol/anti-dinitrophenol perform well in the invention.
  • Other pairs are apparent to the skilled artisan based upon the description of the invention provided below.
  • the primer contains a member of a binding pair at its 5′ terminus
  • the template contains a member of a binding pair at its 3′ terminus
  • the primer contains a member of a binding pair at its 3′ terminus
  • the template contains a member of a binding pair at its 5′ terminus.
  • the template and primer may contain the same type or species of binding pair or they may contain separate types or species. Binding may occur to a single species of binding partner or to separate members of the same species.
  • both the template and the primer are bioinylated at opposite ends oriented to the surface (i.e., one at the 3′ end and one at the 5′ end) and the two biotin molecules adhere to the same streptavidin molecule (which has capacity to bind four biotins) on the surface.
  • the two biotins adhere to separate streptavidin molecules spaced closely together on the surface.
  • the primer is attached to a member of a first binding pair and the template is attached to a member of a second binding pair.
  • the first member attaches to its mate on the surface
  • the second member attaches to its separate mate on the surface.
  • the combination of two separate mating pairs reduces loss of the hybrid due to either the template or the primer dissociating. It is apparent to the skilled artisan based upon this disclosure that any combination of binding pairs works to stabilize hybrid binding to a surface.
  • template and primer may have attached separate species of binder that, although distinct, bind to the same surface-bound mate.
  • the invention comprises methods for sequencing nucleic acids using stabilized, support-bound primer/template hybrids as described above.
  • methods of the invention comprise template-dependent sequencing by synthesis using a polymerase capable of adding nucleotides to the primer in a template-dependent fashion.
  • the invention is particularly useful for single molecule nucleic acid sequencing in which primer/template duplex is attached to a substrate such that the duplex is individually optically resolvable. Individual strand sequence is determined by detecting ordered template-dependent nucleotide incorporation into the primer and compiling a sequence of the template based upon the order of incorporated nucleotides.
  • the invention also provides for the use of a stabilizing molecule in template-dependent sequencing.
  • Stabilizing molecules useful in the invention include, for example, locked nucleic acid (“LNA”) analogs and peptide nucleic acid (“PNA”) analogs.
  • LNA locked nucleic acid
  • PNA peptide nucleic acid
  • a stabilizing molecule increases the affinity and specificity of the primer/target nucleic acid bond, and increases the melting temperature of the primer/target nucleic acid duplex or the specificity of incorporation of a nucleotide into the primer in a sequencing by synthesis reaction.
  • An example of a locked nucleic acid is shown in FIG. 4 . Both locked nucleic acid and peptide nucleic acid analogs increase the melting temperature of the primer/template duplex and, therefore, confer stability on the hybrid, whether or not the anchoring strategies described above are used.
  • Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer.
  • a DNA polymerase an RNA polymerase, or a reverse transcriptase can be used.
  • a thermophilic polymerase is used, such as ThermoSequenase®, 9° NTM, Taq, Tfl, Tth, Tli, Therminator, or Pfu.
  • the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius.
  • a preferred polymerase is a Klenow fragment having reduced 3′-5′ exonuclease activity.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic.
  • preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine.
  • bases of polynucleotide mimetics such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
  • methylated nucleic acids e.g., 2′-O-methRNA
  • peptide nucleic acids e.g., 2′-O-methRNA
  • modified peptide nucleic acids e.g., locked nucleic acids
  • any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation,
  • Nucleotides for primer addition according to the invention preferably comprise a detectable label.
  • Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable.
  • Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxi
  • fluorescence resonance energy transfer is used to determine the base type incorporated into the primer. Fluorescence resonance energy transfer in the context of sequencing is described generally in Braslavasky et al., Sequence Information can be Obtained from Single DNA Molecules , Proc. Nat'l Acad. Sci., 100: 3960-3964 (2003), incorporated by reference herein.
  • a donor fluorophore is attached to either the primer, polymerase, or template.
  • Nucleotides added for incorporation into the primer comprise an acceptor fluorophore that is activated by the donor when the two are in proximity. Activation of the acceptor causes it to emit a characteristic wavelength of light and also quenches the donor.
  • nucleotides labeled with a donor fluorophore also are useful in methods of the invention; FRET-based methods of the invention only require that a donor and acceptor fluorophore pair are used, a labeled nucleotide may comprise one fluorophore and either the template or the polymerase may comprise the other.
  • labeling techniques result in a coincident fluorescent emission of the labels of the nucleotide and the labeled template or polymerase, or alternatively, the fluorescent emission of only one of the labels.
  • the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label.
  • methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity.
  • a label is photocleaved.
  • a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label.
  • Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
  • Preferred substrates include glass, silica, and others with the optical properties described herein.
  • Surfaces for sequencing according to the invention may be coated with, for example, an epoxide, polytetrafluoroethylene or a derivative of polytetrafluoroethylene, such as silanized polytetrafluoroethylene, a polyelectrolyte multilayer (PEM), or the equivalent.
  • PEM polyelectrolyte multilayer
  • Primers useful in the invention hybridize to template in a manner that allows template-dependent sequencing-by-synthesis.
  • the primer may comprise DNA, RNA or a mixture of both.
  • the invention also teaches the use of stabilizing molecules used in connection with the primer or the primer/template duplex, such as locked nucleic acid or peptide nucleic acid analogs.
  • the melting temperature of the primer/target nucleic acid duplex may be increased from about 3° to about 8° Celsius per PNA or LNA base included in the primer.
  • the primer comprises a locked nucleic acid base on its 3′ terminus.
  • the primer may comprise any portion of PNA or LNA bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total nucleic acid residues in the primer.
  • the PNA or LNA bases may be consecutive in the primer or may be interspersed throughout the primer.
  • PNA or LNA bases are spaced apart at a distance of at least one turn of the helix when the primer is hybridized to template.
  • LNA or PNA analogs allows primers to be shorter than would be the case to achieve similar melting temperatures using conventional nucleic acids.
  • the primer comprises fewer than 25 nucleic acids.
  • Methods of the invention are suitable for de novo sequencing, re-sequencing, sequence analysis, DNA fingerprinting, polymorphism identification, for example single nucleotide polymorphisms (SNP) detection, as well as for research and clinical applications in genetics.
  • methods according to the invention also identify alternate splice sites, enumerate copy number, measure gene expression, identify unknown RNA molecules present in cells at low copy number, annotate genomes by determining which sequences are actually transcribed, determine phylogenic relationships, and elucidate differentiation of cells.
  • Methods and surfaces of the invention are useful in diagnostic, therapeutic, prognostic (including drug selection), and developmental applications.
  • FIG. 1 depicts a dual biotinylation reaction securing a primer and target nucleic acid to a substrate.
  • FIG. 2 depicts a primer and target nucleic acid biotinylated to align complementary nucleotides.
  • FIG. 3 depicts three primers comprising locked nucleic acid bases.
  • FIG. 4 depicts the structure of a locked nucleic acid base.
  • FIG. 5 shows the relative stability of dual biotin duplex on a streptavidinated PEM.
  • single molecule sequencing comprises repeated single base extension reactions followed by one or more wash steps. Sequencing occurs on single strands spaced apart such that each strand is individually optically resolvable. Spatial and temporal stability of the individual strands are important in order to preserve the integrity of the sequencing process.
  • template/primer hybridization is a dynamic process. Primer melts off template at a low, but detectable rate. Once melting occurs, at least some portion of primer will be unavailable to re-anneal with template.
  • Methods and surfaces of the invention address this problem by placing stabilizing binding partners on each of the template and primer and, optionally, utilizing stabilizing molecules that confer an increased melting temperature on the primer/template hybrid.
  • a substrate may be made of any suitable material that allows single molecules to be individually optically resolvable.
  • Substrates for use according to the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped.
  • Appropriate substrates include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silica, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.
  • CPG controlled pore glass
  • plastic such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)
  • acrylic copolymer polyamide
  • silica metal (e.g., alkanethiolate-derivatized gold)
  • cellulose e.g., nylon, latex, dextran
  • gel matrix e.
  • a substrate used according to the invention includes a biocompatible or biologically inert material that is transparent to light and optically flat (i.e., with a minimal micro-roughness rating).
  • Specially manufactured, or chemically derivatized, low background fluorescence substrates e.g., glass slides
  • Substrates may be prepared and analyzed on either the top or bottom surface of the planar substrate (i.e., relative to the orientation of the substrate in the detection system).
  • the invention also includes three-dimensional substrates such as spheres, tubes (e.g., capillary tubes), microwells, microfluidic devices, or any other structure suitable for anchoring a nucleic acid.
  • a substrate can be a microparticle, a bead, a membrane, a slide, a plate, a micromachined chip, and the like.
  • Substrates can include planar arrays or matrices capable of having regions that include populations of target nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol; and the like.
  • Factors for selecting substrates include, for example, the material, porosity, size, and shape. Other important factors to be considered in selecting appropriate substrates include size uniformity, efficiency as a synthesis support, and the substrate's optical properties, e.g., clear smooth substrates (free from defects) provide instrumentational advantages when detecting incorporation of nucleotides in single molecules (e.g., nucleic acids.).
  • Substrates are coated with a surface that facilitates nucleic acid binding and that reduces background.
  • Preferred coatings are epoxides, silanized epoxides, biotinylated epoxides, streptavidinated epoxides, polyelecrolyte multilayers, including those that are derivatized for nucleic acid attachment (e.g., biotinylated, streptavidinated, or coated with a binding partner on the template/primer.
  • Surfaces used to attach duplexes according to the invention can be any surface to which a binding partner is capable of attaching.
  • surfaces should be free of debris, especially debris capable of fluorescing.
  • surfaces should be stable and transparent to light.
  • Preferred surfaces are epoxy surfaces and polyelectrolyte multilayer surfaces. Either of those surfaces is easily derivatized as described in the art for attachment of binding pairs.
  • epoxide surfaces are derivatized with silane or other species capable of receiving binding partners.
  • binding pair members attached to template/primer hybrids attach directly to the surface via a molecule embedded in the surface that is not the normal binding partner for the binding pair member.
  • Polyelectrolyte multilayer surfaces are formed from a variety of alternating layers of positive and negative charge. Preferred polyelectrolyte multilayer surfaces are described in detail below.
  • a target nucleic acid for analysis may be obtained from a patient sample, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, breast nipple aspirate, sputum, stool and biopsy tissue. Any tissue or body fluid specimen may be used according to methods of the invention.
  • a target nucleic acid can come from a variety of sources.
  • nucleic acids can be naturally occurring DNA or RNA isolated from any source, recombinant molecules, cDNA, or synthetic analogs, as known in the art.
  • the target nucleic acid may be genomic DNA, genes, gene fragments, exons, introns, regulatory elements (such as promoters, enhancers, initiation and termination regions, expression regulatory factors, expression controls, and other control regions), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, and other mutations.
  • SNPs single-nucleotide polymorphisms
  • allelic variants allelic variants
  • the full genome of one or more cells for example cells from different stages of diseases such as cancer.
  • the target nucleic acid may also be mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, or siRNA.
  • RNA with a recognition site for binding a polymerase, transcripts of a single cell, organelle or microorganism, and all or portions of RNA complements of one or more cells for example, cells from different stages of development or differentiation, and cells from different species.
  • Nucleic acids can be obtained from any cell of a person, animal, plant, bacteria, or virus, including pathogenic microbes or other cellular organisms. Individual nucleic acids can be isolated for analysis.
  • Methods of the invention also contemplate using a stabilizing molecule in a sequencing-by-synthesis reaction.
  • the stabilizing molecule strengthens the primer/template bond and increases the specificity of incorporation of nucleotides into the primer, the melting temperature of the primer/target nucleic acid duplex, or both.
  • a stabilizing molecule may comprise nucleotide or internucleotide analogs, or covalently bound minor groove binders or intercalators that enhance hybridization avidity or specificity of the primer to a target nucleic acid.
  • the internucleotide analogs can comprise one or more of a phosphate ester analog such as alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates and phosphorodithioates.
  • a phosphate ester analog such as alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates and phosphorodithioates.
  • the stabilizing molecule comprises a minor groove binder.
  • Minor groove binders are described in detail in U.S. Pat. No. 6,084,102 which is incorporated by reference in its entirety herein.
  • a minor groove binder has a molecular weight of approximately 150 to approximately 2000 daltons, and typically covalently attaches to at least one of the nucleotides in a duplex. It incorporates into a duplex to strengthen the template/primer bond, thus increasing hybridization stability.
  • a stabilizing molecule may comprise a conformationally restricted nucleotide analog such as a peptide nucleic acid base, a locked nucleic acid base or an oxetane modified base (for a discussion of base constraining oxetane modifications, see U.S. Published Patent Application No. 20040142946, the disclosure of which is incorporated by reference herein).
  • a peptide nucleic acid is a nucleic acid analog in which the backbone comprises synthetic peptide like linkages (amide bonds) usually formed from N-(2-amino-ethyl)-glycine units, resulting in an achiral and uncharged molecule.
  • PNA hybridizes with complementary nucleic acids with high affinity and specificity, and forms PNA/DNA and PNA/RNA duplexes having greater thermal and chemical stability than counterpart DNA/DNA duplexes.
  • a locked nucleic acid is a bicyclic nucleic acid analog that contains one or more 2′-O, 4′-C methylene linkage(s), which effectively locks the furanose ring in a C3′-endo conformation.
  • This methylene linkage “bridge” restricts the flexibility of the ribofuranose ring and locks the structure into a rigid bicyclic formation.
  • locked nucleic acids demonstrate a much greater affinity and specificity to their complementary nucleic acids than do natural DNA counterparts and increases the thermal and chemical stability of a primer/target nucleic acid duplex. LNAs will hybridize to complementary nucleic acids even under adverse conditions, such as under low salt concentrations and in the presence of chaotropic agents.
  • locked nucleic acids increase the melting point of the primer/target nucleic acid duplex by about 30 to about 8° Celsius per locked nucleic acid base incorporated in the primer.
  • FIG. 4 shows an example of the structure of a locked nucleic acid base.
  • the primer may comprise DNA, RNA or a mixture of both.
  • Locked nucleic acid bases may be interspersed throughout a strand of a primer, as shown in FIG. 3 , or may be placed consecutively or singularly in predetermined locations. The amount and placement of the locked nucleic acid bases depends on the desired characteristics of the primer.
  • the primer comprises a locked nucleic acid base at its 3′ terminus.
  • the primer may comprise any portion of locked nucleic acid bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total bases in the primer.
  • primer length is selected to facilitate hybridization to a sufficiently complementary region of the template nucleic acid downstream of the region to be analyzed.
  • the exact lengths of the primers depend on many factors, including temperature and source of primer. Placement of locked nucleic acid bases throughout a primer allows for an increased melting temperature of the primer/target nucleic acid duplex during a sequencing reaction. This also allows the primer length to remain short compared to a primer that does not contain locked nucleic acid bases.
  • Embodiments of this invention include primers with 20 bases or less, which incorporate from 1 to 12 or more locked nucleic acid bases. For example, a 20 base primer which includes 12 locked nucleic acid bases may yield a melting temperature of between about 80° to 90° C. According to one embodiment of the invention, the primer comprises less than about 30, 25, 20, 15, 10, or 5 bases.
  • FIG. 3 shows three exemplary primers (DXS 17, 7G7A, and 377), each containing nine locked nucleic acids and comprising a sequence complementary to a known primer attachment site of a target nucleic acid. While FIG. 3 shows primers of known sequences complementary to a known region of a template, primers useful in the invention also include primers comprising a random sequences. Useful primers also include primers comprising a sequence that is complementary to a known priming region that has been ligated to a target nucleic acid.
  • Primers can be synthetically made using conventional nucleic acid synthesis techniques. For example, primers are synthesized on an automated DNA synthesizer (e.g., Applied Biosystems, Inc., Foster City, Calif.) using standard chemistries, such as phosphoramidite chemistry, and the like. Alternative chemistries, e.g., resulting in non-natural backbone groups, such as phosphorothioate, phosphoramidate, and the like, may also be employed provided that, for example, the resulting oligonucleotides are compatible with the polymerizing agent.
  • the primers can also be ordered commercially from a variety of companies which specialize in custom nucleic acids such as Operon, Inc. (Alameda, Calif.). Primers comprising locked nucleic acids are purchased commercially (Proligo® LLC, Boulder, Colo.) or prepared as needed by methods known in the art.
  • the foregoing methods confer a significant advantage in single molecule reactions, in which one is tracking nucleotide incorporation into individual template/primer duplexes.
  • Single molecule techniques provide the ability to observe discrete differences within and between individuals in terms of nucleotide sequence. Disruption of a hybrid impairs the ability to obtain full advantage from single molecule techniques because the loss of a hybrid represents the loss of significant information content relative to a bulk reaction in which there exist numerous copies of each hybrid pair. Methods of the invention maximize the ability to keep hybrid pairs intact and attached to substrate.
  • annealing Conditions for hybridizing primers to target nucleic acids are known in the art.
  • the annealing reaction is performed under conditions which are stringent enough to ensure sequence specificity, yet sufficiently permissive to allow formation of stable hybrids at an acceptable rate.
  • the temperature and length of time required for primer annealing depend upon several factors including the base composition, length and concentration of the primer, and the nature of the solvent used, e.g., the concentration of cosolvents such as DMSO (dimethylsulfoxide), formamide, or glycerol, and counterions such as magnesium.
  • hybridization annealing
  • hybridization is carried out at a temperature that is approximately 5 to 10° Celsius below the melting temperature of the primer/target nucleic acid duplex in the annealing solvent. Annealing temperatures may be modified based on the amount of locked nucleic acid included in the primer, based on manufacturer's recommendation and methods known in the art.
  • the primer/target nucleic acid duplex is exposed to a polymerase, and at least one nucleotide or nucleotide analog under conditions that allow for incorporation of the nucleotide into the primer.
  • Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependant addition of a nucleotide to a primer, such as, Klenow, Vent ThermoSequenase®, 9° NTM, Therminator, Taq, Tfl, Tth, Tli, Pfu, and others.
  • a thermophilic polymerase is used.
  • the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius, or at least about 50°, 60°, or 70° Celsius.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic.
  • preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine.
  • bases of polynucleotide mimetics such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids, oxetane-modified bases and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
  • Nucleotides particularly useful in the invention comprise detectable labels.
  • Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable.
  • Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a flu
  • fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); 5′5′′-dibromopyrogallol-sulfonaphthalein (Bromopyroga
  • the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label.
  • methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity.
  • a label is photocleaved.
  • a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label.
  • Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
  • the primer or the target nucleic acid can also include a detectable label.
  • the label When the labeled primer and/or target nucleic acid are attached to the substrate, the label facilitates locating the bound molecule through imaging.
  • the primer or target nucleic acid can be labeled with a fluorescent labeling moiety (e.g., Cy3 or Cy5), or any other means used to label nucleotides.
  • the detectable label used to label the primer or target nucleic acid can be different from the label used on the nucleotides or nucleotide analogs in the subsequent extension reactions. Additionally, once the molecule has been localized, it may be desirable to render the label undetectable prior to the nucleotide incorporation detection steps by methods such as washing or photobleaching.
  • a nucleotide analog according to the invention can be modified to remove, cap or modify the 3′ hydroxyl group.
  • methods of the invention can include, for example, the step of removing the 3′ hydroxyl group from the incorporated nucleotide or nucleotide analog. By removing the 3′ hydroxyl group from the incorporated nucleotide in the primer, further extension is halted or impeded.
  • the modified nucleotide can be engineered so that the 3′ hydroxyl group can be removed and/or added by chemical methods.
  • a nucleotide analog can be modified to include a moiety that is sufficiently large to prevent or sterically hinder further chain elongation by interfering with the polymerase, thereby halting incorporation of additional nucleotides or nucleotide analogs. Subsequent removal of the moiety, or at least the steric-hindering portion of the moiety, can concomitantly reverse chain termination and allow chain elongation to proceed.
  • the moiety also can be a label.
  • chemically cleaving or photocleaving the blocking moiety may also chemically-bleach or photobleach the label, respectively.
  • Incorporation of a nucleotide or a nucleotide analog and their locations on the surface of a substrate can be detected with single molecule sensitivity according to the invention.
  • single molecule resolution is achieved by anchoring a target nucleic acid at a low concentration to a substrate, and then imaging nucleotide incorporation with for example, with total internal reflection fluorescence microscopy.
  • a number of detection methods are available for use in single molecule analysis.
  • Methods for visualizing single molecules within nucleic acids labeled with an intercalating dye include, for example, fluorescence microscopy. For example, the fluorescent spectrum and lifetime of a single molecule excited-state can be measured. Standard detectors such as a photomultiplier tube or avalanche photodiode can be used. Full field imaging with a two-stage image intensified COD camera also can be used. Additionally, low noise cooled CCD can also be used to detect single fluorescent molecules.
  • the detection system for the signal may depend upon the labeling moiety used, which can be defined by the chemistry available.
  • a combination of an optical fiber or CCD can be used in the detection step.
  • the substrate is itself transparent to the radiation used, it is possible to have an incident light beam pass through the substrate with the detector located opposite the substrate from the primer.
  • electromagnetic labels various forms of spectroscopy systems can be used.
  • Various physical orientations for the detection system are available and known in the art.
  • Optical systems include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy.
  • methods involve detection of laser-activated fluorescence using a microscope equipped with a camera, sometimes referred to as high-efficiency photon detection system.
  • Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras.
  • an intensified charge couple device (ICCD) camera can be used.
  • ICCD intensified charge couple device
  • the use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.
  • biotin/avidin binding pairs When a biotin-streptavidin linkage is used to anchor a primer and a target nucleic acid to a substrate, the primer and target nucleic acid are biotinylated, while the surface of the substrate is coated with streptavidin. Because streptavidin is a tetramer, it is possible that both template and primer will bind to the same surface streptavidin. However, the dual biotin labels may bind to adjacent streptavidin molecules as well.
  • the PEM surfaces were amine-derivatized by treatment with 10 mM NHS and 10 mM EDC in 0.1 M MES buffer, pH 6.0, 05M NaCl (coupling buffer) for 15 minutes. The surfaces were then rinsed twice in the coupling buffer and incubated for 1 hour in 0.1 mg/ml Streptavidin Plus (SA-20, Prozyme) in the coupling buffer.
  • 10 mM NHS and 10 mM EDC in 0.1 M MES buffer, pH 6.0, 05M NaCl (coupling buffer) for 15 minutes.
  • the surfaces were then rinsed twice in the coupling buffer and incubated for 1 hour in 0.1 mg/ml Streptavidin Plus (SA-20, Prozyme) in the coupling buffer.
  • the resulting streptavidinated surfaces were rinsed in a 200 ⁇ l solution of dual-biotin duplex in which the primer had the sequence: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1) and the template had the sequence: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT -TEG-Biotin (SEQ ID NO: 2; primer binding region bolded and underlined).
  • the terminal thymidine was labeled with cyanine-5 dye and the adenine two positions 5′ of the terminus was labeled with a cyanine-3 dye.
  • the dual biotin duplexes referred to above were first bound to a streptavidinated PEM surface as described above. The surface was then exposed to 100 nM unlabeled biotin at 52° C. for 10 minutes. As a control, streptavidinated PEMs were incubated in parallel and then rinsed with dual-biotin duplex. All slides then were washed, imaged, and analyzed as described above. The data are shown in FIG. 5 . The results indicate that the dual-biotin duplexes on a streptavidinated PEM surface are surface-stable.
  • Another experiment shows the stability of dual-biotin duplexes in single molecule sequencing.
  • streptavidinated slides are prepared on a PEM as described above. The slides then are biotinylated. Fresh biotin-long chain polyethyloxide-amine (Biotin-LC-PEO, Pierce) is prepared in MES buffer (50 mg Biotin in 2.5 ml MES). A 5 ml aliquot of the EDC solution described above is combined with 5 ml of the Biotin-LC-PEO solution and diluted in MES buffer to a total volume of 96 ml by adding 86 ml of MES buffer to a 2.5 mM final EDC-biotin concentration.
  • the PEM-coated slides are then immersed in that solution in a 100 ml beaker and incubated for 60 minutes at room temperature.
  • the slides are then rinsed in MES buffer with gentle agitation for 10 seconds. Immersion and rinsing are repeated four times in clean 100 ml volumes. Slides are then incubated in the final bath for 10 minutes.
  • the resulting biotin-coated slides are stored in Tris-NaCl buffer prior to streptavidination.
  • Streptavidin-Plus (SA20, Prozyme) isdissolved in a solution of 10 mM NaCl buffer at 0.14 mg/ml and stirred 10 minutes at room temperature to thoroughly dissolve flakes. The resulting solution is filtered with a 0.22 ⁇ filter. Biotinylated slides described above are placed in this solution in a 100 ml beaker with a stir bar and stirred for 15 minutes at room temperature. The slides are then rinsed in 100 ml Tris-NaCl buffer with gentle agitation for 10 seconds. The rinse process is repeated 5 times in clean 100 ml volumes of 3 ⁇ SSC-0.1% Triton, incubating in the final bath for 10 minutes. Finally, the slides are transferred to a fresh bath of Tris-NaCl and agitated for 10 seconds. Slides arestored in Tris-NaCl buffer at 4° C. prior to use.
  • 3′ bioinylated target nucleic acid templates 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2), are obtained from Integrated DNA Technologies (Coral, Iowa).
  • 5′ biotinylated primers 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1), comprising a cyanine-5 dye were hybridized to the templates and exposed to the streptavidinated surfaces described above at a concentration of 10 pM.
  • the surfaces are washed with MES buffer and the surface was imaged using a Nikon TE-2000U upright microscope equipped with a total internal reflection objective (Nikon).
  • the location of label represented the location of bound hybrid and the positions of label are noted. Positional detection can also be accomplished using unlabeled template/primer and adding labeled first base.
  • nucleotide additions are accomplished using the Klenow fragment (exo-) polymerase (New England Biolabs) at 10 mM in Ecopol reaction buffer and a series of cyanine-labeled nucleotide triphosphates.
  • an oxygen scavenging system is used (glucose (0.36%), glucose oxidase (8 U/ml), catalase (423 U/ml), Trolox (5 mM), Gallate (5 mM), DABCO (10 mM), and 2,4,6-octatrienoic acid).
  • cyanine-5-labeled primer The positions of cyanine-5-labeled primer are recorded and bleached.
  • dUTP-Cy3 in polymerase is added to the slides. If dUTP is incorporated into the primer, fluorescence resonance energy transfer (FRET) from the cyanine-5 on the primer will caus the cyanine-3 dye to emit and the location of the emission is detected.
  • FRET fluorescence resonance energy transfer
  • the cyanine-3 dye is kept unbleached and subsequent additions are with cyanine-5-labeled dNTPs, using FRET with cyanine-3 as the donor for detection of incorporation.
  • FRET fluorescence resonance energy transfer
  • a primer is designed to be complementary to a known primer attachment site of the target nucleic acid, and locked nucleic acid bases are substituted for certain nucleotides within the selected primer sequence. As many locked nucleic acid bases are selected as desired depending on the temperature and length of primer, up to a primer comprising 100% locked nucleic acids. The more locked nucleic acid substitutions into the primer, the greater the melting point of the primer/target nucleic acid duplex relative a primer of the same length lacking locked nucleic acid residues.
  • FIG. 3 shows three primers synthesized with locked nucleic acids.
  • DXS17, 7G7A, and 377 primers were synthesized as complementary strands to known regions of a template, each primer incorporating nine locked nucleic acids. When these primers are annealed to their respective templates, hybridization may be carried out at temperatures between about 80° C. to about 90° C.

Abstract

The invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex on a substrate. Methods of the invention generally contemplate the use of a dual-anchored primer/target nucleic acid duplex, or a stabilizing molecule in a single molecule sequencing reaction.

Description

    TECHNICAL FIELD OF THE INVENTION
  • The invention provides methods for sequencing a nucleic acid comprising stabilizing a primer/target nucleic acid duplex attached to a substrate. Generally, methods of the invention comprise the use of a dual-anchored primer/target nucleic acid duplex or stabilizing molecule.
  • BACKGROUND OF THE INVENTION
  • Completion of the human genome has paved the way for important insights into biologic structure and function. Knowledge of the human genome has given rise to inquiry into individual differences, as well as differences within an individual, as the basis for differences in biological function and dysfunction. For example, single nucleotide differences between individuals, called single nucleotide polymorphisms (SNPs), are responsible for dramatic phenotypic differences. Those differences can be outward expressions of phenotype or can involve the likelihood that an individual will get a specific disease or how that individual will respond to treatment. Moreover, subtle genomic changes have been shown to be responsible for the manifestation of genetic diseases, such as cancer. A true understanding of the duplexities in either normal or abnormal function will require large amounts of specific sequence information.
  • An understanding of cancer also requires an understanding of genomic sequence duplexity. Cancer is a disease that is rooted in heterogeneous genomic instability. Most cancers develop from a series of genomic changes, some subtle and some significant, that occur in a small subpopulation of cells. Knowledge of the sequence variations that lead to cancer will lead to an understanding of the etiology of the disease, as well as ways to treat and prevent it. An essential first step in understanding genomic duplexity is the ability to perform high-resolution sequencing.
  • Various approaches to nucleic acid sequencing exist. One conventional way to do bulk sequencing is by chain termination and gel separation, essentially as described by Sanger et al., Proc. Natl. Acad. Sci., 74(12): 5463-67 (1977). That method relies on the generation of a mixed population of nucleic acid fragments representing terminations at each base in a sequence. The fragments are then run on an electrophoretic gel and the sequence is revealed by the order of fragments in the gel. Another conventional bulk sequencing method relies on chemical degradation of nucleic acid fragments. See, Maxam et al., Proc. Natl. Acad. Sci., 74: 560-564 (1977). Finally, methods have been developed based upon sequencing by hybridization. See, e.g., Drrnanac, et al., Nature Biotech., 16: 54-58 (1998).
  • Bulk sequencing techniques are not useful for the identification of subtle or rare nucleotide changes due to the many cloning, amplification and electrophoresis steps that complicate the process of gaining useful information regarding individual nucleotides. The ability to sequence and gain information from single molecules obtained from an individual patient is the next milestone for genomic sequencing. As such, research has evolved toward methods for rapid sequencing, such as single molecule sequencing technologies.
  • There have been many proposals to develop new sequencing technologies based on single-molecule measurements, generally either by observing the interaction of particular proteins with DNA or by using ultra high resolution scanned probe microscopy. See, e.g., Rigler, et al., DNA-Sequencing at the Single Molecule Level, Journal of Biotechnology, 86(3): 161 (2001); Goodwin, P. M., et al., Application of Single Molecule Detection to DNA Sequencing. Nucleosides & Nucleotides, 16(5-6): 543-550 (1997); Howorka, S., et al., Sequence-Specific Detection of Individual DNA Strands using Engineered Nanopores, Nature Biotechnology, 19(7): 636-639 (2001); Meller, A., et al., Rapid Nanopore Discrimination Between Single Polynucleotide Molecules, Proceedings of the National Academy of Sciences of the United States of America, 97(3): 1079-1084 (2000); Driscoll, R. J., et al., Atomic-Scale Imaging of DNA Using Scanning Tunneling Microscopy. Nature, 346(6281): 294-296 (1990). Unlike conventional sequencing technologies, their speed and read-length would not be inherently limited by the resolving power of electrophoretic separation. Other methods proposed for single molecule sequencing include detecting individual nucleotides as they are incorporated into a primed template, i.e., sequencing by synthesis.
  • While single molecule techniques have several advantages, implementation has been problematic. For example, the reproducibility and accuracy of many single molecule techniques rely upon the stability of a primer/target nucleic acid duplex attached to a solid substrate. However, incomplete binding of the primer to the template, disengagement of the primer from the template and disengagement of the duplex from the substrate are frequent occurrences in such single molecule techniques.
  • Accordingly, there is a need in the art for methods and devices for sequencing generally, and single molecule sequencing in particular, including methods for stabilizing a target nucleic acid for sequence determination.
  • SUMMARY OF THE INVENTION
  • The invention generally provides methods and surfaces for nucleic acid sequencing comprising stabilized primer/target nucleic acid duplexes on a surface. Methods of the invention generally contemplate the use of a primer/target nucleic acid duplex in which each of the primer and the template contain a molecule having a binding partner on the substrate. The primer/target is stabilized on the surface by binding of both the primer and the template to the surface. Binding pairs for use in the invention are any molecular pair that can be bound to a surface and attached to a nucleic acid. Some examples of preferred pairs include ligand/receptor, affinity pairs, antigen/antibody, and carbohydrate/lectin. For example, biotin/streptavidin, digoxigenin/anti-digoxigenin, and dinitrophenol/anti-dinitrophenol perform well in the invention. Other pairs are apparent to the skilled artisan based upon the description of the invention provided below.
  • According to the invention, the primer contains a member of a binding pair at its 5′ terminus, and the template contains a member of a binding pair at its 3′ terminus or the primer contains a member of a binding pair at its 3′ terminus and the template contains a member of a binding pair at its 5′ terminus. Thus, the primer hybridizes to the template, and the two attached binding pair members are oriented to bind to their respective mates on the surface.
  • The template and primer may contain the same type or species of binding pair or they may contain separate types or species. Binding may occur to a single species of binding partner or to separate members of the same species. For example, in one embodiment, both the template and the primer are bioinylated at opposite ends oriented to the surface (i.e., one at the 3′ end and one at the 5′ end) and the two biotin molecules adhere to the same streptavidin molecule (which has capacity to bind four biotins) on the surface. Alternatively, the two biotins adhere to separate streptavidin molecules spaced closely together on the surface. In another embodiment, the primer is attached to a member of a first binding pair and the template is attached to a member of a second binding pair. Upon hybridization, the first member attaches to its mate on the surface, and the second member attaches to its separate mate on the surface. In either embodiment, the combination of two separate mating pairs reduces loss of the hybrid due to either the template or the primer dissociating. It is apparent to the skilled artisan based upon this disclosure that any combination of binding pairs works to stabilize hybrid binding to a surface. For example, template and primer may have attached separate species of binder that, although distinct, bind to the same surface-bound mate.
  • The invention comprises methods for sequencing nucleic acids using stabilized, support-bound primer/template hybrids as described above. In a preferred embodiment, methods of the invention comprise template-dependent sequencing by synthesis using a polymerase capable of adding nucleotides to the primer in a template-dependent fashion. The invention is particularly useful for single molecule nucleic acid sequencing in which primer/template duplex is attached to a substrate such that the duplex is individually optically resolvable. Individual strand sequence is determined by detecting ordered template-dependent nucleotide incorporation into the primer and compiling a sequence of the template based upon the order of incorporated nucleotides.
  • The invention also provides for the use of a stabilizing molecule in template-dependent sequencing. Stabilizing molecules useful in the invention include, for example, locked nucleic acid (“LNA”) analogs and peptide nucleic acid (“PNA”) analogs. Generally, a stabilizing molecule increases the affinity and specificity of the primer/target nucleic acid bond, and increases the melting temperature of the primer/target nucleic acid duplex or the specificity of incorporation of a nucleotide into the primer in a sequencing by synthesis reaction. An example of a locked nucleic acid is shown in FIG. 4. Both locked nucleic acid and peptide nucleic acid analogs increase the melting temperature of the primer/template duplex and, therefore, confer stability on the hybrid, whether or not the anchoring strategies described above are used.
  • Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependent addition of a nucleotide or nucleotide analog to a primer. Depending on the characteristics of the target nucleic acid, a DNA polymerase, an RNA polymerase, or a reverse transcriptase can be used. According to one aspect of the invention, a thermophilic polymerase is used, such as ThermoSequenase®, 9° N™, Taq, Tfl, Tth, Tli, Therminator, or Pfu. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius. A preferred polymerase is a Klenow fragment having reduced 3′-5′ exonuclease activity.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
  • Nucleotides for primer addition according to the invention preferably comprise a detectable label. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.
  • In one embodiment, fluorescence resonance energy transfer (FRET) is used to determine the base type incorporated into the primer. Fluorescence resonance energy transfer in the context of sequencing is described generally in Braslavasky et al., Sequence Information can be Obtained from Single DNA Molecules, Proc. Nat'l Acad. Sci., 100: 3960-3964 (2003), incorporated by reference herein. Essentially, in one embodiment, a donor fluorophore is attached to either the primer, polymerase, or template. Nucleotides added for incorporation into the primer comprise an acceptor fluorophore that is activated by the donor when the two are in proximity. Activation of the acceptor causes it to emit a characteristic wavelength of light and also quenches the donor. In this way, incorporation of a nucleotide in the primer sequence is detected by detection of acceptor emission. Of course, nucleotides labeled with a donor fluorophore also are useful in methods of the invention; FRET-based methods of the invention only require that a donor and acceptor fluorophore pair are used, a labeled nucleotide may comprise one fluorophore and either the template or the polymerase may comprise the other. Such labeling techniques result in a coincident fluorescent emission of the labels of the nucleotide and the labeled template or polymerase, or alternatively, the fluorescent emission of only one of the labels.
  • In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
  • Preferred substrates include glass, silica, and others with the optical properties described herein. Surfaces for sequencing according to the invention may be coated with, for example, an epoxide, polytetrafluoroethylene or a derivative of polytetrafluoroethylene, such as silanized polytetrafluoroethylene, a polyelectrolyte multilayer (PEM), or the equivalent.
  • Primers useful in the invention hybridize to template in a manner that allows template-dependent sequencing-by-synthesis. Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. The invention also teaches the use of stabilizing molecules used in connection with the primer or the primer/template duplex, such as locked nucleic acid or peptide nucleic acid analogs. According to the invention, the melting temperature of the primer/target nucleic acid duplex may be increased from about 3° to about 8° Celsius per PNA or LNA base included in the primer. In one embodiment, the primer comprises a locked nucleic acid base on its 3′ terminus. The primer may comprise any portion of PNA or LNA bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total nucleic acid residues in the primer. The PNA or LNA bases may be consecutive in the primer or may be interspersed throughout the primer. In a preferred embodiment, PNA or LNA bases are spaced apart at a distance of at least one turn of the helix when the primer is hybridized to template. The use of LNA or PNA analogs allows primers to be shorter than would be the case to achieve similar melting temperatures using conventional nucleic acids. According to one embodiment of the invention, the primer comprises fewer than 25 nucleic acids.
  • Methods of the invention are suitable for de novo sequencing, re-sequencing, sequence analysis, DNA fingerprinting, polymorphism identification, for example single nucleotide polymorphisms (SNP) detection, as well as for research and clinical applications in genetics. Applied to RNA sequences, methods according to the invention also identify alternate splice sites, enumerate copy number, measure gene expression, identify unknown RNA molecules present in cells at low copy number, annotate genomes by determining which sequences are actually transcribed, determine phylogenic relationships, and elucidate differentiation of cells. Methods and surfaces of the invention are useful in diagnostic, therapeutic, prognostic (including drug selection), and developmental applications.
  • As will be appreciated by one skilled in the art, individual features of the invention may be used separately or in any combination. A detailed description of embodiments of the invention is provided below. Other embodiments of the invention are apparent upon review of the detailed description that follows.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts a dual biotinylation reaction securing a primer and target nucleic acid to a substrate.
  • FIG. 2 depicts a primer and target nucleic acid biotinylated to align complementary nucleotides.
  • FIG. 3 depicts three primers comprising locked nucleic acid bases.
  • FIG. 4 depicts the structure of a locked nucleic acid base.
  • FIG. 5 shows the relative stability of dual biotin duplex on a streptavidinated PEM.
  • DETAILED DESCRIPTION
  • The results of single molecule sequencing are influenced by the stability of substrate-bound primer/target nucleic acid duplexes. Typically, single molecule sequencing comprises repeated single base extension reactions followed by one or more wash steps. Sequencing occurs on single strands spaced apart such that each strand is individually optically resolvable. Spatial and temporal stability of the individual strands are important in order to preserve the integrity of the sequencing process. One way in which the spatial stability of a single molecule array can be disrupted is if the template and/or primer become disassociated with the surface. For example, template/primer hybridization is a dynamic process. Primer melts off template at a low, but detectable rate. Once melting occurs, at least some portion of primer will be unavailable to re-anneal with template. That is not necessarily a problem in a bulk sequencing reaction in which numerous copies of each template are available for sequencing. However, in single molecule sequencing, in which individual strands are sequenced, loss of any strand can have a significant effect on the result. Methods and surfaces of the invention address this problem by placing stabilizing binding partners on each of the template and primer and, optionally, utilizing stabilizing molecules that confer an increased melting temperature on the primer/template hybrid.
  • I. General Considerations
  • Substrates
  • Generally, a substrate may be made of any suitable material that allows single molecules to be individually optically resolvable. Substrates for use according to the invention can be two- or three-dimensional and can comprise a planar surface (e.g., a glass slide) or can be shaped. Appropriate substrates include glass (e.g., controlled pore glass (CPG)), quartz, plastic (such as polystyrene (low cross-linked and high cross-linked polystyrene), polycarbonate, polypropylene and poly(methymethacrylate)), acrylic copolymer, polyamide, silica, metal (e.g., alkanethiolate-derivatized gold), cellulose, nylon, latex, dextran, gel matrix (e.g., silica gel), polyacrolein, or composites.
  • Preferably, a substrate used according to the invention includes a biocompatible or biologically inert material that is transparent to light and optically flat (i.e., with a minimal micro-roughness rating). Specially manufactured, or chemically derivatized, low background fluorescence substrates (e.g., glass slides) are also contemplated according to the invention. Substrates may be prepared and analyzed on either the top or bottom surface of the planar substrate (i.e., relative to the orientation of the substrate in the detection system).
  • The invention also includes three-dimensional substrates such as spheres, tubes (e.g., capillary tubes), microwells, microfluidic devices, or any other structure suitable for anchoring a nucleic acid. For example, a substrate can be a microparticle, a bead, a membrane, a slide, a plate, a micromachined chip, and the like. Substrates can include planar arrays or matrices capable of having regions that include populations of target nucleic acids or primers. Examples include nucleoside-derivatized CPG and polystyrene slides; derivatized magnetic slides; polystyrene grafted with polyethylene glycol; and the like.
  • Factors for selecting substrates include, for example, the material, porosity, size, and shape. Other important factors to be considered in selecting appropriate substrates include size uniformity, efficiency as a synthesis support, and the substrate's optical properties, e.g., clear smooth substrates (free from defects) provide instrumentational advantages when detecting incorporation of nucleotides in single molecules (e.g., nucleic acids.).
  • Substrates are coated with a surface that facilitates nucleic acid binding and that reduces background. Preferred coatings are epoxides, silanized epoxides, biotinylated epoxides, streptavidinated epoxides, polyelecrolyte multilayers, including those that are derivatized for nucleic acid attachment (e.g., biotinylated, streptavidinated, or coated with a binding partner on the template/primer.
  • Surfaces
  • Surfaces used to attach duplexes according to the invention can be any surface to which a binding partner is capable of attaching. For sequencing, surfaces should be free of debris, especially debris capable of fluorescing. Also, surfaces should be stable and transparent to light. Preferred surfaces are epoxy surfaces and polyelectrolyte multilayer surfaces. Either of those surfaces is easily derivatized as described in the art for attachment of binding pairs. For example, epoxide surfaces are derivatized with silane or other species capable of receiving binding partners. In certain embodiments, binding pair members attached to template/primer hybrids attach directly to the surface via a molecule embedded in the surface that is not the normal binding partner for the binding pair member. Polyelectrolyte multilayer surfaces are formed from a variety of alternating layers of positive and negative charge. Preferred polyelectrolyte multilayer surfaces are described in detail below.
  • Target Nucleic Acids
  • A target nucleic acid for analysis may be obtained from a patient sample, e.g., from blood, urine, cerebrospinal fluid, seminal fluid, saliva, breast nipple aspirate, sputum, stool and biopsy tissue. Any tissue or body fluid specimen may be used according to methods of the invention.
  • A target nucleic acid can come from a variety of sources. For example, nucleic acids can be naturally occurring DNA or RNA isolated from any source, recombinant molecules, cDNA, or synthetic analogs, as known in the art. For example, the target nucleic acid may be genomic DNA, genes, gene fragments, exons, introns, regulatory elements (such as promoters, enhancers, initiation and termination regions, expression regulatory factors, expression controls, and other control regions), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, and other mutations. Also included is the full genome of one or more cells, for example cells from different stages of diseases such as cancer. The target nucleic acid may also be mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, or siRNA. Also contemplated according to the invention are RNA with a recognition site for binding a polymerase, transcripts of a single cell, organelle or microorganism, and all or portions of RNA complements of one or more cells, for example, cells from different stages of development or differentiation, and cells from different species. Nucleic acids can be obtained from any cell of a person, animal, plant, bacteria, or virus, including pathogenic microbes or other cellular organisms. Individual nucleic acids can be isolated for analysis.
  • Stabilizing Molecules and Primers
  • Methods of the invention also contemplate using a stabilizing molecule in a sequencing-by-synthesis reaction. The stabilizing molecule strengthens the primer/template bond and increases the specificity of incorporation of nucleotides into the primer, the melting temperature of the primer/target nucleic acid duplex, or both. A stabilizing molecule may comprise nucleotide or internucleotide analogs, or covalently bound minor groove binders or intercalators that enhance hybridization avidity or specificity of the primer to a target nucleic acid. The internucleotide analogs can comprise one or more of a phosphate ester analog such as alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates and phosphorodithioates.
  • In one aspect, the stabilizing molecule comprises a minor groove binder. Minor groove binders are described in detail in U.S. Pat. No. 6,084,102 which is incorporated by reference in its entirety herein. Generally, a minor groove binder has a molecular weight of approximately 150 to approximately 2000 daltons, and typically covalently attaches to at least one of the nucleotides in a duplex. It incorporates into a duplex to strengthen the template/primer bond, thus increasing hybridization stability.
  • In one embodiment, a stabilizing molecule may comprise a conformationally restricted nucleotide analog such as a peptide nucleic acid base, a locked nucleic acid base or an oxetane modified base (for a discussion of base constraining oxetane modifications, see U.S. Published Patent Application No. 20040142946, the disclosure of which is incorporated by reference herein). A peptide nucleic acid is a nucleic acid analog in which the backbone comprises synthetic peptide like linkages (amide bonds) usually formed from N-(2-amino-ethyl)-glycine units, resulting in an achiral and uncharged molecule. PNA hybridizes with complementary nucleic acids with high affinity and specificity, and forms PNA/DNA and PNA/RNA duplexes having greater thermal and chemical stability than counterpart DNA/DNA duplexes.
  • A locked nucleic acid is a bicyclic nucleic acid analog that contains one or more 2′-O, 4′-C methylene linkage(s), which effectively locks the furanose ring in a C3′-endo conformation. This methylene linkage “bridge” restricts the flexibility of the ribofuranose ring and locks the structure into a rigid bicyclic formation. Because of its unique structural conformation, locked nucleic acids demonstrate a much greater affinity and specificity to their complementary nucleic acids than do natural DNA counterparts and increases the thermal and chemical stability of a primer/target nucleic acid duplex. LNAs will hybridize to complementary nucleic acids even under adverse conditions, such as under low salt concentrations and in the presence of chaotropic agents. According to one aspect of the invention, locked nucleic acids increase the melting point of the primer/target nucleic acid duplex by about 30 to about 8° Celsius per locked nucleic acid base incorporated in the primer. FIG. 4 shows an example of the structure of a locked nucleic acid base.
  • Depending on the target nucleic acid, the primer may comprise DNA, RNA or a mixture of both. Locked nucleic acid bases may be interspersed throughout a strand of a primer, as shown in FIG. 3, or may be placed consecutively or singularly in predetermined locations. The amount and placement of the locked nucleic acid bases depends on the desired characteristics of the primer. In one embodiment, the primer comprises a locked nucleic acid base at its 3′ terminus. The primer may comprise any portion of locked nucleic acid bases, such as between about 10% and about 50%, more than about 50%, or less than about 10%, 20%, 30%, 40%, 50% or 60% of the total bases in the primer.
  • In general, primer length is selected to facilitate hybridization to a sufficiently complementary region of the template nucleic acid downstream of the region to be analyzed. The exact lengths of the primers depend on many factors, including temperature and source of primer. Placement of locked nucleic acid bases throughout a primer allows for an increased melting temperature of the primer/target nucleic acid duplex during a sequencing reaction. This also allows the primer length to remain short compared to a primer that does not contain locked nucleic acid bases. Embodiments of this invention include primers with 20 bases or less, which incorporate from 1 to 12 or more locked nucleic acid bases. For example, a 20 base primer which includes 12 locked nucleic acid bases may yield a melting temperature of between about 80° to 90° C. According to one embodiment of the invention, the primer comprises less than about 30, 25, 20, 15, 10, or 5 bases.
  • FIG. 3 shows three exemplary primers (DXS 17, 7G7A, and 377), each containing nine locked nucleic acids and comprising a sequence complementary to a known primer attachment site of a target nucleic acid. While FIG. 3 shows primers of known sequences complementary to a known region of a template, primers useful in the invention also include primers comprising a random sequences. Useful primers also include primers comprising a sequence that is complementary to a known priming region that has been ligated to a target nucleic acid.
  • Primers can be synthetically made using conventional nucleic acid synthesis techniques. For example, primers are synthesized on an automated DNA synthesizer (e.g., Applied Biosystems, Inc., Foster City, Calif.) using standard chemistries, such as phosphoramidite chemistry, and the like. Alternative chemistries, e.g., resulting in non-natural backbone groups, such as phosphorothioate, phosphoramidate, and the like, may also be employed provided that, for example, the resulting oligonucleotides are compatible with the polymerizing agent. The primers can also be ordered commercially from a variety of companies which specialize in custom nucleic acids such as Operon, Inc. (Alameda, Calif.). Primers comprising locked nucleic acids are purchased commercially (Proligo® LLC, Boulder, Colo.) or prepared as needed by methods known in the art.
  • The foregoing methods confer a significant advantage in single molecule reactions, in which one is tracking nucleotide incorporation into individual template/primer duplexes. Single molecule techniques provide the ability to observe discrete differences within and between individuals in terms of nucleotide sequence. Disruption of a hybrid impairs the ability to obtain full advantage from single molecule techniques because the loss of a hybrid represents the loss of significant information content relative to a bulk reaction in which there exist numerous copies of each hybrid pair. Methods of the invention maximize the ability to keep hybrid pairs intact and attached to substrate.
  • Primer Hybridization
  • Conditions for hybridizing primers to target nucleic acids are known in the art. The annealing reaction is performed under conditions which are stringent enough to ensure sequence specificity, yet sufficiently permissive to allow formation of stable hybrids at an acceptable rate. The temperature and length of time required for primer annealing depend upon several factors including the base composition, length and concentration of the primer, and the nature of the solvent used, e.g., the concentration of cosolvents such as DMSO (dimethylsulfoxide), formamide, or glycerol, and counterions such as magnesium. Typically, hybridization (annealing) is carried out at a temperature that is approximately 5 to 10° Celsius below the melting temperature of the primer/target nucleic acid duplex in the annealing solvent. Annealing temperatures may be modified based on the amount of locked nucleic acid included in the primer, based on manufacturer's recommendation and methods known in the art.
  • Primer Extension and Labeling
  • During primer extension, the primer/target nucleic acid duplex is exposed to a polymerase, and at least one nucleotide or nucleotide analog under conditions that allow for incorporation of the nucleotide into the primer. Polymerases useful in the invention include any polymerizing agent capable of catalyzing a template-dependant addition of a nucleotide to a primer, such as, Klenow, Vent ThermoSequenase®, 9° N™, Therminator, Taq, Tfl, Tth, Tli, Pfu, and others. According to one aspect of the invention, a thermophilic polymerase is used. In one embodiment, the invention provides for the primer/target nucleic acid duplex to be exposed to the polymerase and nucleotide at a temperature between about 30° and about 80° Celsius, or at least about 50°, 60°, or 70° Celsius.
  • Nucleotides useful in the invention include any nucleotide or nucleotide analog, whether naturally-occurring or synthetic. For example, preferred nucleotides are adenine, cytosine, guanine, uracil, or thymine bases; xanthine or hypoxanthine, 5-bromouracil, 2-aminopurine, deoxyinosine, or methylated cytosine, such as 5-methylcytosine, and N4-methoxydeoxycytosine. Also included are bases of polynucleotide mimetics, such as methylated nucleic acids, e.g., 2′-O-methRNA, peptide nucleic acids, modified peptide nucleic acids, locked nucleic acids, oxetane-modified bases and any other structural moiety that can act substantially like a nucleotide or base, for example, by exhibiting base-complementarity with one or more bases that occur in DNA or RNA and/or being capable of base-complementary incorporation, and includes chain-terminating analogs.
  • Nucleotides particularly useful in the invention comprise detectable labels. Labeled nucleotides include any nucleotide that has been modified to include a label that is directly or indirectly detectable. Preferred labels include optically-detectable labels, including fluorescent labels or fluorophores, such as fluorescein, rhodamine, derivatized rhodamine dyes, such as TAMRA, phosphor, polymethadine dye, fluorescent phosphoramidite, Texas Red, green fluorescent protein, acridine, cyanine, cyanine 5 dye, cyanine 3 dye, 5-(2′-aminoethyl)-aminonaphthalene-1-sulfonic acid (EDANS), BODIPY, 120 ALEXA or a derivative or modification of any of the foregoing, and also include such labeling systems as hapten labeling. Accordingly, methods of the invention further provide for exposing the primer/target nucleic acid duplex to a digoxigenin, a fluorescein, an alkaline phosphatase or a peroxidase.
  • Other suitable fluorescent labels include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid; acridine and derivatives: acridine, acridine isothiocyanate; 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate; N-(4-anilino-1-naphthyl)maleimide; anthranilamide; Brilliant Yellow; coumarin and derivatives; coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-4-trifluoromethylcouluarin (Coumaran 151); cyanine dyes; cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI); 5′5″-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red); 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid; 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid; 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansylchloride); 4-dimethylaminophenylazophenyl-4′-isothiocyanate (DABITC); eosin and derivatives; eosin, eosin isothiocyanate, erythrosin and derivatives; erythrosin B, erythrosin, isothiocyanate; ethidium; fluorescein derivatives; 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF), 2′,7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein isothiocyanate, QFITC, (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferoneortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; o-phthaldialdehyde; pyrene and derivatives: pyrene, pyrene butyrate, succinimidyl 1-pyrene; butyrate quantum dots; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A) rhodamine and derivatives: 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine; tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid; terbium chelate derivatives; Cy5.5; Cy7; IRD 700; IRD 800; La Jolta Blue; phthalo cyanine; and naphthalo cyanine.
  • In a preferred embodiment, after detection, the label is rendered undetectable by removing the label from the nucleotide or extended primer, neutralizing the label, or masking the label. In certain embodiments, methods according to the invention provide for neutralizing a label by photobleaching. This is accomplished by focusing a laser with a short laser pulse, for example, for a short duration of time with increasing laser intensity. In other embodiments, a label is photocleaved. For example, a light-sensitive label bound to a nucleotide is photocleaved by focusing a particular wavelength of light on the label. Generally, it may be preferable to use lasers having differing wavelengths for exciting and photocleaving. Labels also can be chemically cleaved. Labels may be removed from a substrate using reagents, such as NaOH or other appropriate buffer reagent.
  • Further, the primer or the target nucleic acid can also include a detectable label. When the labeled primer and/or target nucleic acid are attached to the substrate, the label facilitates locating the bound molecule through imaging. The primer or target nucleic acid can be labeled with a fluorescent labeling moiety (e.g., Cy3 or Cy5), or any other means used to label nucleotides. The detectable label used to label the primer or target nucleic acid can be different from the label used on the nucleotides or nucleotide analogs in the subsequent extension reactions. Additionally, once the molecule has been localized, it may be desirable to render the label undetectable prior to the nucleotide incorporation detection steps by methods such as washing or photobleaching.
  • A nucleotide analog according to the invention can be modified to remove, cap or modify the 3′ hydroxyl group. As such, in certain embodiments, methods of the invention can include, for example, the step of removing the 3′ hydroxyl group from the incorporated nucleotide or nucleotide analog. By removing the 3′ hydroxyl group from the incorporated nucleotide in the primer, further extension is halted or impeded. In certain embodiments, the modified nucleotide can be engineered so that the 3′ hydroxyl group can be removed and/or added by chemical methods. Alternatively, a nucleotide analog can be modified to include a moiety that is sufficiently large to prevent or sterically hinder further chain elongation by interfering with the polymerase, thereby halting incorporation of additional nucleotides or nucleotide analogs. Subsequent removal of the moiety, or at least the steric-hindering portion of the moiety, can concomitantly reverse chain termination and allow chain elongation to proceed. In some embodiments, the moiety also can be a label. As such, in those embodiments, chemically cleaving or photocleaving the blocking moiety may also chemically-bleach or photobleach the label, respectively.
  • Detection of Incorporated Nucleotides
  • Incorporation of a nucleotide or a nucleotide analog and their locations on the surface of a substrate can be detected with single molecule sensitivity according to the invention. In some aspects of the invention, single molecule resolution is achieved by anchoring a target nucleic acid at a low concentration to a substrate, and then imaging nucleotide incorporation with for example, with total internal reflection fluorescence microscopy.
  • A number of detection methods are available for use in single molecule analysis. Methods for visualizing single molecules within nucleic acids labeled with an intercalating dye include, for example, fluorescence microscopy. For example, the fluorescent spectrum and lifetime of a single molecule excited-state can be measured. Standard detectors such as a photomultiplier tube or avalanche photodiode can be used. Full field imaging with a two-stage image intensified COD camera also can be used. Additionally, low noise cooled CCD can also be used to detect single fluorescent molecules.
  • The detection system for the signal may depend upon the labeling moiety used, which can be defined by the chemistry available. For optical signals, a combination of an optical fiber or CCD can be used in the detection step. In the embodiments where the substrate is itself transparent to the radiation used, it is possible to have an incident light beam pass through the substrate with the detector located opposite the substrate from the primer. For electromagnetic labels, various forms of spectroscopy systems can be used. Various physical orientations for the detection system are available and known in the art.
  • A number of approaches can be used to detect incorporation of fluorescently-labeled nucleotides into a single molecule. Optical systems include near-field scanning microscopy, far-field confocal microscopy, wide-field epi-illumination, light scattering, dark field microscopy, photoconversion, single and/or multiphoton excitation, spectral wavelength discrimination, fluorophore identification, evanescent wave illumination, and total internal reflection fluorescence (TIRF) microscopy. In general, methods involve detection of laser-activated fluorescence using a microscope equipped with a camera, sometimes referred to as high-efficiency photon detection system. Suitable photon detection systems include, but are not limited to, photodiodes and intensified CCD cameras. For example, as illustrated in FIG. 2, an intensified charge couple device (ICCD) camera can be used. The use of an ICCD camera to image individual fluorescent dye molecules in a fluid near a surface provides numerous advantages. For example, with an ICCD optical setup, it is possible to acquire a sequence of images (movies) of fluorophores.
  • Certain embodiments of the invention are described in the following examples, which are not meant to be limiting.
  • II. EXAMPLES Example 1 Dual Biotinylation
  • General methods of the invention were demonstrated using biotin/avidin binding pairs. When a biotin-streptavidin linkage is used to anchor a primer and a target nucleic acid to a substrate, the primer and target nucleic acid are biotinylated, while the surface of the substrate is coated with streptavidin. Because streptavidin is a tetramer, it is possible that both template and primer will bind to the same surface streptavidin. However, the dual biotin labels may bind to adjacent streptavidin molecules as well.
  • Two experiments were done to determine the binding stability of the dual biotin constructs. A first experiment was conducted in order to determine the stability of dual biotin duplex on a polyelectrolyte multilayer (PEM) surface. This experiment was done using covalent streptavidin attachment to a PEM surface. The PEM surfaces were prepared as follows. Polyethyleneimine (PEI) and pollyallylamine (PAA, Sigma, St. Louis, Mo.) were dissolved separately by stirring in MilliQ water and the pH was adjusted to 8.0 with dilute HCl. The solutions were filtered using a 0.22μ filter flask and stored at 4° C. Clean glass slides were then alternatively immersed for 10 minutes in the PEI and PAA solutions four times each with an 8 minute rinse using MilliQ water between each immersion. After the last rinse, the slides were kept immersed in water. The slides were then transferred to MES buffer (2-[N-morpholino] ethanesulfonic acid), pH 5.5 for EDC-induced crosslinking of the PEM. A 10 mM solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) was prepared in MES buffer, filtered and added to the solution containing the PEM-coated slides for 1 hour at room temperature. Slides were then rinsed in MES buffer and stored.
  • Next, the PEM surfaces were amine-derivatized by treatment with 10 mM NHS and 10 mM EDC in 0.1 M MES buffer, pH 6.0, 05M NaCl (coupling buffer) for 15 minutes. The surfaces were then rinsed twice in the coupling buffer and incubated for 1 hour in 0.1 mg/ml Streptavidin Plus (SA-20, Prozyme) in the coupling buffer. The resulting streptavidinated surfaces were rinsed in a 200 μl solution of dual-biotin duplex in which the primer had the sequence: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1) and the template had the sequence: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2; primer binding region bolded and underlined). At its 3′ end, the terminal thymidine was labeled with cyanine-5 dye and the adenine two positions 5′ of the terminus was labeled with a cyanine-3 dye. Surfaces were soaked for 5 minutes and then rinsed once in 20 mM Tris, pH 8.0, 50 mM NaCl, 0.01% Triton (Rinse Buffer). The surfaces were then rinsed 5 times in 3×SSC-0.1% Triton, with a 10 minute soak in the last rinse. Finally, the surfaces were rinsed in two changes of the Rinse Buffer. The resulting surface had dual-biotin primer/target nucleic acid duplex bound to streptavidin. A second set of slides was rinsed with the dual biotin duplexes as described above, but was also challenged with 100 nM unlabeled biotin. All slides were imaged over a 1000μ2 area and analyzed in ImagePro (Media Cybernetics, San Diego) using a dark image background subtraction algorithm.
  • Visualization of surface-bound duplexes was accomplished using fluorescence resonance energy transfer (FRET), with the cyanine-5 labeled thymidine as the donor and the cyanine-3 labeled adenine as the acceptor. Slides were placed on a Nikon Eclipse TE-2000 inverted microscope with a total internal reflection objective. The dual-biotin duplex slides showed 309.7 counts/pixel and the biotin-challenged slides showed 10.1 counts/pixel. These results indicate that the dual-biotin duplexes were binding to streptavidin on the PEM in a specific manner, as the cold biotin was able to compete away duplex binding.
  • In a separate experiment, the dual biotin duplexes referred to above were first bound to a streptavidinated PEM surface as described above. The surface was then exposed to 100 nM unlabeled biotin at 52° C. for 10 minutes. As a control, streptavidinated PEMs were incubated in parallel and then rinsed with dual-biotin duplex. All slides then were washed, imaged, and analyzed as described above. The data are shown in FIG. 5. The results indicate that the dual-biotin duplexes on a streptavidinated PEM surface are surface-stable.
  • Another experiment shows the stability of dual-biotin duplexes in single molecule sequencing. For this experiment, streptavidinated slides are prepared on a PEM as described above. The slides then are biotinylated. Fresh biotin-long chain polyethyloxide-amine (Biotin-LC-PEO, Pierce) is prepared in MES buffer (50 mg Biotin in 2.5 ml MES). A 5 ml aliquot of the EDC solution described above is combined with 5 ml of the Biotin-LC-PEO solution and diluted in MES buffer to a total volume of 96 ml by adding 86 ml of MES buffer to a 2.5 mM final EDC-biotin concentration. The PEM-coated slides are then immersed in that solution in a 100 ml beaker and incubated for 60 minutes at room temperature. The slides are then rinsed in MES buffer with gentle agitation for 10 seconds. Immersion and rinsing are repeated four times in clean 100 ml volumes. Slides are then incubated in the final bath for 10 minutes. The resulting biotin-coated slides are stored in Tris-NaCl buffer prior to streptavidination.
  • Streptavidin-Plus (SA20, Prozyme) isdissolved in a solution of 10 mM NaCl buffer at 0.14 mg/ml and stirred 10 minutes at room temperature to thoroughly dissolve flakes. The resulting solution is filtered with a 0.22μ filter. Biotinylated slides described above are placed in this solution in a 100 ml beaker with a stir bar and stirred for 15 minutes at room temperature. The slides are then rinsed in 100 ml Tris-NaCl buffer with gentle agitation for 10 seconds. The rinse process is repeated 5 times in clean 100 ml volumes of 3×SSC-0.1% Triton, incubating in the final bath for 10 minutes. Finally, the slides are transferred to a fresh bath of Tris-NaCl and agitated for 10 seconds. Slides arestored in Tris-NaCl buffer at 4° C. prior to use.
  • 3′ bioinylated target nucleic acid templates: 5′-TCA GCT GCG TCA GCT AGC GAC AGT AAA GGA TAA GTG CAT AAG GGG TTT TT-TEG-Biotin (SEQ ID NO: 2), are obtained from Integrated DNA Technologies (Coral, Iowa). 5′ biotinylated primers: 5′-Biotin-TEG-AA AAA CCC CTT ATG CAC TTA TCC TTT ACT (SEQ ID NO: 1), comprising a cyanine-5 dye were hybridized to the templates and exposed to the streptavidinated surfaces described above at a concentration of 10 pM. After incubation for 10 minutes, the surfaces are washed with MES buffer and the surface was imaged using a Nikon TE-2000U upright microscope equipped with a total internal reflection objective (Nikon). The location of label represented the location of bound hybrid and the positions of label are noted. Positional detection can also be accomplished using unlabeled template/primer and adding labeled first base. To determine the stability of bound duplexes, nucleotide additions are accomplished using the Klenow fragment (exo-) polymerase (New England Biolabs) at 10 mM in Ecopol reaction buffer and a series of cyanine-labeled nucleotide triphosphates. To reduce bleaching of the fluorescent dyes, an oxygen scavenging system is used (glucose (0.36%), glucose oxidase (8 U/ml), catalase (423 U/ml), Trolox (5 mM), Gallate (5 mM), DABCO (10 mM), and 2,4,6-octatrienoic acid).
  • The positions of cyanine-5-labeled primer are recorded and bleached. dUTP-Cy3 in polymerase is added to the slides. If dUTP is incorporated into the primer, fluorescence resonance energy transfer (FRET) from the cyanine-5 on the primer will caus the cyanine-3 dye to emit and the location of the emission is detected. The cyanine-3 dye is kept unbleached and subsequent additions are with cyanine-5-labeled dNTPs, using FRET with cyanine-3 as the donor for detection of incorporation. The results show that dual-biotin duplex is a stable template for template-dependent sequencing.
  • The skilled artisan understands that there are numerous other embodiments of the invention in terms of surfaces, binding partners and the like that can be manipulated in order to achieve the stability results shown above.
  • Example 2 Locked Nucleic Acid
  • A primer is designed to be complementary to a known primer attachment site of the target nucleic acid, and locked nucleic acid bases are substituted for certain nucleotides within the selected primer sequence. As many locked nucleic acid bases are selected as desired depending on the temperature and length of primer, up to a primer comprising 100% locked nucleic acids. The more locked nucleic acid substitutions into the primer, the greater the melting point of the primer/target nucleic acid duplex relative a primer of the same length lacking locked nucleic acid residues.
  • FIG. 3 shows three primers synthesized with locked nucleic acids. DXS17, 7G7A, and 377 primers were synthesized as complementary strands to known regions of a template, each primer incorporating nine locked nucleic acids. When these primers are annealed to their respective templates, hybridization may be carried out at temperatures between about 80° C. to about 90° C.
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (8)

1. A surface for nucleic acid sequencing, said surface comprising a nucleic acid duplex composed of a template and a primer, each of said template and primer being attached to a member of a binding pair, such that each of said members is oriented toward said surface.
2. The surface of claim 1, wherein each duplex is individually optically resolvable.
3. The surface of claim 1, wherein said surface is a polyelectrolyte multilayer.
4. The surface of claim 1, wherein said surface is an epoxide surface.
5. The surface of claim 1, wherein said surface is deposited on a substrate selected from the group consisting of glass and silica.
6. The surface of claim 1, wherein binding partners of said members are covalently attached to said surface.
7. The surface of claim 1, wherein said binding pair is selected from the group consisting of a ligand/receptor pair, an affinity binding pair, an antigen/antibody pair, and a carbohydrate/lectin pair.
8. The surface of claim 7, wherein said pair is selected from the group consisting of biotin/avidin, digoxigenin/anit-digoxigenin, and dintirophenol/anti-dinitrophenol.
US11/413,381 2004-12-30 2006-04-27 Stabilizing a nucleic acid for nucleic acid sequencing Abandoned US20060252077A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/413,381 US20060252077A1 (en) 2004-12-30 2006-04-27 Stabilizing a nucleic acid for nucleic acid sequencing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/027,165 US7220549B2 (en) 2004-12-30 2004-12-30 Stabilizing a nucleic acid for nucleic acid sequencing
US11/413,381 US20060252077A1 (en) 2004-12-30 2006-04-27 Stabilizing a nucleic acid for nucleic acid sequencing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/027,165 Division US7220549B2 (en) 2004-12-30 2004-12-30 Stabilizing a nucleic acid for nucleic acid sequencing

Publications (1)

Publication Number Publication Date
US20060252077A1 true US20060252077A1 (en) 2006-11-09

Family

ID=36640913

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/027,165 Expired - Fee Related US7220549B2 (en) 2004-12-30 2004-12-30 Stabilizing a nucleic acid for nucleic acid sequencing
US11/413,381 Abandoned US20060252077A1 (en) 2004-12-30 2006-04-27 Stabilizing a nucleic acid for nucleic acid sequencing
US11/709,338 Abandoned US20080085840A1 (en) 2004-12-30 2007-02-20 Stabilizing a nucleic acid for nucleic acid sequencing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/027,165 Expired - Fee Related US7220549B2 (en) 2004-12-30 2004-12-30 Stabilizing a nucleic acid for nucleic acid sequencing

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/709,338 Abandoned US20080085840A1 (en) 2004-12-30 2007-02-20 Stabilizing a nucleic acid for nucleic acid sequencing

Country Status (1)

Country Link
US (3) US7220549B2 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157641A1 (en) * 2007-06-18 2008-12-24 Applera Corporation Method and compositions for nucleic acid amplification
US20090156412A1 (en) * 2007-12-17 2009-06-18 Helicos Biosciences Corporation Surface-capture of target nucleic acids
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
EP2975059A1 (en) 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
DE202015009002U1 (en) 2014-07-15 2016-08-18 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US9810610B2 (en) 2014-09-17 2017-11-07 Hologic, Inc. Method of partial lysis and assay
WO2018053362A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation
WO2018085599A2 (en) 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018098362A1 (en) 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens
WO2019023924A1 (en) 2017-08-01 2019-02-07 Helitec Limited Methods of enriching and determining target nucleotide sequences
US10683531B2 (en) 2016-09-15 2020-06-16 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free DNA
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US11183286B2 (en) 2015-12-16 2021-11-23 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
US11264117B2 (en) 2017-10-10 2022-03-01 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP4026912A1 (en) 2012-05-10 2022-07-13 The General Hospital Corporation Methods for determining a nucleotide sequence
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2022204321A1 (en) 2021-03-24 2022-09-29 Ambry Genetics Corporation Conservative concurrent evaluation of dna modifications
US11504421B2 (en) 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2023004344A1 (en) 2021-07-20 2023-01-26 Regeneron Pharmaceuticals, Inc. Butyrophilin-like 2 for treating inflammatory disorders
US11591619B2 (en) 2019-05-30 2023-02-28 Gritstone Bio, Inc. Modified adenoviruses
EP4219744A2 (en) 2014-01-27 2023-08-02 The General Hospital Corporation Methods of preparing nucleic acids for sequencing
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US11771747B2 (en) 2020-08-06 2023-10-03 Gritstone Bio, Inc. Multiepitope vaccine cassettes
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105388A1 (en) * 2002-12-23 2006-05-18 Febit Biothch Gmbh Incorporation of hapten groups during the production of carriers for the determination of analytes
WO2004092331A2 (en) * 2003-04-08 2004-10-28 Li-Cor, Inc. Composition and method for nucleic acid sequencing
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
CN105039313B (en) 2005-06-23 2018-10-23 科因股份有限公司 For the high throughput identification of polymorphism and the strategy of detection
DK1929039T4 (en) * 2005-09-29 2014-02-17 Keygene Nv High throughput-screening af mutageniserede populationer
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
US20070190542A1 (en) * 2005-10-03 2007-08-16 Ling Xinsheng S Hybridization assisted nanopore sequencing
WO2007070642A2 (en) * 2005-12-15 2007-06-21 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
PL2789696T3 (en) 2005-12-22 2016-06-30 Keygene Nv Method for high-throughput AFLP-based polymorphism detection
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
ES2545264T3 (en) 2006-04-04 2015-09-09 Keygene N.V. High performance detection of molecular markers based on restriction fragments
EP3543357A1 (en) 2007-05-08 2019-09-25 Trustees of Boston University Chemical functionalization of solid-state nanopores and nanopore arrays and applications thereof
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
WO2009046094A1 (en) 2007-10-01 2009-04-09 Nabsys, Inc. Biopolymer sequencing by hybridization of probes to form ternary complexes and variable range alignment
US7767441B2 (en) * 2007-10-25 2010-08-03 Industrial Technology Research Institute Bioassay system including optical detection apparatuses, and method for detecting biomolecules
US7811810B2 (en) 2007-10-25 2010-10-12 Industrial Technology Research Institute Bioassay system including optical detection apparatuses, and method for detecting biomolecules
CN101910399B (en) 2007-10-30 2015-11-25 考利达基因组股份有限公司 For the device of high throughput sequencing of nucleic acids
US9551026B2 (en) 2007-12-03 2017-01-24 Complete Genomincs, Inc. Method for nucleic acid detection using voltage enhancement
EP2252625B1 (en) 2008-02-07 2017-12-20 Pacific Biosciences of California, Inc. Cis reactive oxygen quenchers integrated into linkers
US8158405B2 (en) * 2008-06-30 2012-04-17 General Electric Company Process for concentrating and processing fluid samples
US8546127B2 (en) * 2008-06-30 2013-10-01 General Electric Company Bacteria/RNA extraction device
US9650668B2 (en) 2008-09-03 2017-05-16 Nabsys 2.0 Llc Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels
JP5717634B2 (en) * 2008-09-03 2015-05-13 ナブシス, インコーポレイテッド Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluid channels
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
US20100184045A1 (en) * 2008-09-23 2010-07-22 Helicos Biosciences Corporation Methods for sequencing degraded or modified nucleic acids
MY188457A (en) * 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
WO2010056728A1 (en) * 2008-11-11 2010-05-20 Helicos Biosciences Corporation Nucleic acid encoding for multiplex analysis
US8927511B2 (en) * 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
MX358603B (en) 2008-12-04 2018-08-28 Curna Inc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
CN102317458B (en) * 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
US8986933B2 (en) 2008-12-05 2015-03-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Selective detection of human rhinovirus
PL2396038T3 (en) 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
EP2411536B1 (en) * 2009-03-27 2014-09-17 Nabsys, Inc. Methods for analyzing biomolecules and probes bound thereto
US8455260B2 (en) * 2009-03-27 2013-06-04 Massachusetts Institute Of Technology Tagged-fragment map assembly
CN106237345A (en) 2009-05-06 2016-12-21 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
US20120046236A1 (en) 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459597B (en) 2009-05-08 2020-06-30 库尔纳公司 Treatment of dystrophin family-related diseases by inhibition of natural antisense transcript to DMD family
JP5922017B2 (en) 2009-05-18 2016-05-24 クルナ・インコーポレーテッド Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
JP2012527248A (en) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド Treatment of TFE3 and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against transcription factor E3 (TFE3)
US8246799B2 (en) * 2009-05-28 2012-08-21 Nabsys, Inc. Devices and methods for analyzing biomolecules and probes bound thereto
JP5960049B2 (en) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes
CN102612560B (en) 2009-06-16 2017-10-17 库尔纳公司 By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1)
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011011700A2 (en) 2009-07-24 2011-01-27 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
CN104313027B (en) 2009-08-11 2018-11-20 库尔纳公司 By inhibiting the natural antisense transcript of adiponectin (ADIPOQ) to treat adiponectin (ADIPOQ) related disease
KR101805213B1 (en) 2009-08-21 2017-12-06 큐알엔에이, 인크. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US9566335B1 (en) 2009-09-25 2017-02-14 The Governing Council Of The University Of Toronto Protein sequencing method and reagents
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
KR101823702B1 (en) 2009-12-16 2018-01-30 큐알엔에이, 인크. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー,インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
JP6083735B2 (en) 2009-12-31 2017-02-22 カッパーアールエヌエー,インコーポレイテッド Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against insulin receptor substrate 2 (IRS2) and transcription factor 3 (TFE3)
NO2521784T3 (en) 2010-01-04 2018-05-05
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
EP2539452B1 (en) 2010-02-22 2016-07-27 CuRNA, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CN102869777B (en) 2010-04-02 2018-11-02 库尔纳公司 CSF3 relevant diseases are treated by inhibiting the natural antisense transcript of colony stimulating factor 3 (CSF3)
EP3517613A1 (en) 2010-04-09 2019-07-31 CuRNA, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
KR20130101442A (en) 2010-05-03 2013-09-13 큐알엔에이, 인크. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
PL2585596T3 (en) 2010-06-23 2021-06-28 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
EP2596127A2 (en) 2010-07-23 2013-05-29 Esoterix Genetic Laboratories, LLC Identification of differentially represented fetal or maternal genomic regions and uses thereof
US8715933B2 (en) 2010-09-27 2014-05-06 Nabsys, Inc. Assay methods using nicking endonucleases
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012067911A1 (en) 2010-11-16 2012-05-24 Nabsys, Inc. Methods for sequencing a biomolecule by detecting relative positions of hybridized probes
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US11274341B2 (en) 2011-02-11 2022-03-15 NABsys, 2.0 LLC Assay methods using DNA binding proteins
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
WO2013036403A1 (en) 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9803239B2 (en) 2012-03-29 2017-10-31 Complete Genomics, Inc. Flow cells for high density array chips
US9651539B2 (en) 2012-10-28 2017-05-16 Quantapore, Inc. Reducing background fluorescence in MEMS materials by low energy ion beam treatment
US9914966B1 (en) 2012-12-20 2018-03-13 Nabsys 2.0 Llc Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation
EP2956550B1 (en) 2013-01-18 2020-04-08 Nabsys 2.0 LLC Enhanced probe binding
US9862997B2 (en) 2013-05-24 2018-01-09 Quantapore, Inc. Nanopore-based nucleic acid analysis with mixed FRET detection
ES2789000T3 (en) 2014-10-10 2020-10-23 Quantapore Inc Nanopore-based polynucleotide analysis with mutually inactivating fluorescent labels
JP6757316B2 (en) 2014-10-24 2020-09-16 クアンタポール, インコーポレイテッド Efficient optical analysis of polymers using nanostructured arrays
EP3482196B1 (en) 2016-07-05 2022-02-23 Quantapore, Inc. Optically based nanopore sequencing

Citations (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725677A (en) * 1983-08-18 1988-02-16 Biosyntech Gmbh Process for the preparation of oligonucleotides
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4811218A (en) * 1986-06-02 1989-03-07 Applied Biosystems, Inc. Real time scanning electrophoresis apparatus for DNA sequencing
US4994373A (en) * 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US4994368A (en) * 1987-07-23 1991-02-19 Syntex (U.S.A.) Inc. Amplification method for polynucleotide assays
US4994372A (en) * 1987-01-14 1991-02-19 President And Fellows Of Harvard College DNA sequencing
US5085562A (en) * 1989-04-11 1992-02-04 Westonbridge International Limited Micropump having a constant output
US5091652A (en) * 1990-01-12 1992-02-25 The Regents Of The University Of California Laser excited confocal microscope fluorescence scanner and method
US5096554A (en) * 1989-08-07 1992-03-17 Applied Biosystems, Inc. Nucleic acid fractionation by counter-migration capillary electrophoresis
US5096388A (en) * 1990-03-22 1992-03-17 The Charles Stark Draper Laboratory, Inc. Microfabricated pump
US5108892A (en) * 1989-08-03 1992-04-28 Promega Corporation Method of using a taq dna polymerase without 5'-3'-exonuclease activity
US5198540A (en) * 1982-10-28 1993-03-30 Hubert Koster Process for the preparation of oligonucleotides in solution
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5304487A (en) * 1992-05-01 1994-04-19 Trustees Of The University Of Pennsylvania Fluid handling in mesoscale analytical devices
US5306403A (en) * 1992-08-24 1994-04-26 Martin Marietta Energy Systems, Inc. Raman-based system for DNA sequencing-mapping and other separations
US5484701A (en) * 1990-01-26 1996-01-16 E. I. Du Pont De Nemours And Company Method for sequencing DNA using biotin-strepavidin conjugates to facilitate the purification of primer extension products
US5492806A (en) * 1987-04-01 1996-02-20 Hyseq, Inc. Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5610287A (en) * 1993-12-06 1997-03-11 Molecular Tool, Inc. Method for immobilizing nucleic acid molecules
US5705018A (en) * 1995-12-13 1998-01-06 Hartley; Frank T. Micromachined peristaltic pump
US5707506A (en) * 1994-10-28 1998-01-13 Battelle Memorial Institute Channel plate for DNA sequencing
US5710628A (en) * 1994-12-12 1998-01-20 Visible Genetics Inc. Automated electrophoresis and fluorescence detection apparatus and method
US5712476A (en) * 1995-05-30 1998-01-27 Visible Genetics Inc. Electrophoresis and fluorescence detection apparatus
US5733729A (en) * 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5858671A (en) * 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US5861287A (en) * 1995-06-23 1999-01-19 Baylor College Of Medicine Alternative dye-labeled primers for automated DNA sequencing
US5863722A (en) * 1994-10-13 1999-01-26 Lynx Therapeutics, Inc. Method of sorting polynucleotides
US5872244A (en) * 1994-09-02 1999-02-16 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5876934A (en) * 1996-12-18 1999-03-02 Pharmacia Biotech Inc. DNA sequencing method
US5876187A (en) * 1995-03-09 1999-03-02 University Of Washington Micropumps with fixed valves
US5882904A (en) * 1997-08-04 1999-03-16 Amersham Pharmacia Biotech Inc. Thermococcus barossii DNA polymerase mutants
US5885813A (en) * 1995-05-31 1999-03-23 Amersham Life Science, Inc. Thermostable DNA polymerases
US5889165A (en) * 1989-06-07 1999-03-30 Affymetrix, Inc. Photolabile nucleoside protecting groups
US6015714A (en) * 1995-03-17 2000-01-18 The United States Of America As Represented By The Secretary Of Commerce Characterization of individual polymer molecules based on monomer-interface interactions
US6017702A (en) * 1996-12-05 2000-01-25 The Perkin-Elmer Corporation Chain-termination type nucleic acid sequencing method including 2'-deoxyuridine-5'-triphosphate
US6020457A (en) * 1996-09-30 2000-02-01 Dendritech Inc. Disulfide-containing dendritic polymers
US6024925A (en) * 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
US6026136A (en) * 1994-08-16 2000-02-15 Radkowsky Thorium Power Corp. Seed-blanket reactors
US6028190A (en) * 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6030782A (en) * 1997-03-05 2000-02-29 Orchid Biocomputer, Inc. Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds
US6043080A (en) * 1995-06-29 2000-03-28 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6177249B1 (en) * 1995-12-18 2001-01-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
US6197506B1 (en) * 1989-06-07 2001-03-06 Affymetrix, Inc. Method of detecting nucleic acids
US6207960B1 (en) * 1996-05-16 2001-03-27 Affymetrix, Inc System and methods for detection of labeled materials
US6207381B1 (en) * 1996-04-04 2001-03-27 Biacore Ab Method for nucleic acid analysis
US6335824B1 (en) * 1998-03-20 2002-01-01 Genetic Microsystems, Inc. Wide field of view and high speed scanning microscopy
US6337188B1 (en) * 1997-11-21 2002-01-08 Orchid Biosciences, Inc. De novo or “universal” sequencing array
US6337185B1 (en) * 1995-11-16 2002-01-08 Amersham Pharmacia Biotech Ab Method of sequencing
US20020009744A1 (en) * 1998-08-18 2002-01-24 Valery Bogdanov In-line complete spectral fluorescent imaging of nucleic acid molecules
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
US20020012910A1 (en) * 1993-10-22 2002-01-31 Robert B. Weiss Automated hybridization/imaging device for fluorescent multiplex dna sequencing
US6344325B1 (en) * 1996-09-25 2002-02-05 California Institute Of Technology Methods for analysis and sorting of polynucleotides
US20020015961A1 (en) * 1999-10-05 2002-02-07 Marek Kwiatkowski Compounds for protecting hydroxyls and methods for their use
US6346413B1 (en) * 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US6346379B1 (en) * 1997-09-11 2002-02-12 F. Hoffman-La Roche Ag Thermostable DNA polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes
US20020025529A1 (en) * 1999-06-28 2002-02-28 Stephen Quake Methods and apparatus for analyzing polynucleotide sequences
US6355420B1 (en) * 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US20020032320A1 (en) * 1998-12-18 2002-03-14 The Texas A&M University System Methods of labelling biomolecules with fluorescent dyes
US20020034792A1 (en) * 1996-12-20 2002-03-21 Christian Kilger Method for the uncoupled, direct, exponential amplification and sequencing of dna molecules with the addition of a second thermostable dna polymerase and its application
US6361671B1 (en) * 1999-01-11 2002-03-26 The Regents Of The University Of California Microfabricated capillary electrophoresis chip and method for simultaneously detecting multiple redox labels
US6361937B1 (en) * 1996-03-19 2002-03-26 Affymetrix, Incorporated Computer-aided nucleic acid sequencing
US20030003498A1 (en) * 1996-04-18 2003-01-02 Digby Thomas J. Method, apparatus and kits for sequencing of nucleic acids using multiple dyes
US20030003272A1 (en) * 2001-06-21 2003-01-02 Bruno Laguitton Polyanion/polycation multilayer film for DNA immobilization
US20030008285A1 (en) * 2001-06-29 2003-01-09 Fischer Steven M. Method of DNA sequencing using cleavable tags
US20030008413A1 (en) * 2001-07-02 2003-01-09 Namyong Kim Methods of making and using substrate surfaces having covalently bound polyelectrolyte films
US6506560B1 (en) * 1994-09-30 2003-01-14 Invitrogen Corporation Cloned DNA polymerases from Thermotoga and mutants thereof
US20030017461A1 (en) * 2000-07-11 2003-01-23 Aclara Biosciences, Inc. Tag cleavage for detection of nucleic acids
US6511803B1 (en) * 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US6514706B1 (en) * 1998-10-26 2003-02-04 Christoph Von Kalle Linear amplification mediated PCR (LAM PCR)
US20030027140A1 (en) * 2001-03-30 2003-02-06 Jingyue Ju High-fidelity DNA sequencing using solid phase capturable dideoxynucleotides and mass spectrometry
US6521428B1 (en) * 1999-04-21 2003-02-18 Genome Technologies, Llc Shot-gun sequencing and amplification without cloning
US20030036080A1 (en) * 1998-08-11 2003-02-20 Caliper Technologies Corp. DNA sequencing using multiple flourescent labels being distinguishable by their decay times
US6524829B1 (en) * 1998-09-30 2003-02-25 Molecular Machines & Industries Gmbh Method for DNA- or RNA-sequencing
US20030039738A1 (en) * 2000-06-26 2003-02-27 Cheuk Wai Lun Pet food composition and method
US6528258B1 (en) * 1999-09-03 2003-03-04 Lifebeam Technologies, Inc. Nucleic acid sequencing using an optically labeled pore
US20030044779A1 (en) * 1991-03-05 2003-03-06 Philip Goelet Nucleic acid typing by polymerase extension of oligonucleotides using terminator mixtures
US20030044778A1 (en) * 1991-03-05 2003-03-06 Philip Goelet Nucleic acid typing by polymerase extension of oligonucleotides using terminator mixtures
US20030044781A1 (en) * 1999-05-19 2003-03-06 Jonas Korlach Method for sequencing nucleic acid molecules
US20030044816A1 (en) * 1995-03-17 2003-03-06 Denison Timothy J. Characterization of individual polymer molecules based on monomer-interface interactions
US20030054181A1 (en) * 2001-01-12 2003-03-20 Harold Swerdlow Substrate for fluorescence analysis
US20030054361A1 (en) * 1991-11-07 2003-03-20 Nanogen, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
US6537755B1 (en) * 1999-03-25 2003-03-25 Radoje T. Drmanac Solution-based methods and materials for sequence analysis by hybridization
US6537757B1 (en) * 1997-03-05 2003-03-25 The Regents Of The University Of Michigan Nucleic acid sequencing and mapping
US20030058799A1 (en) * 2001-09-24 2003-03-27 Mineo Yamakawa Nucleic acid sequencing by raman monitoring of molecular deconstruction
US20030059778A1 (en) * 2001-09-24 2003-03-27 Andrew Berlin Nucleic acid sequencing by Raman monitoring of uptake of precursors during molecular replication
US20030060431A1 (en) * 1997-07-31 2003-03-27 Nycomed Amersham Plc Base analogues
US20030058440A1 (en) * 2001-08-28 2003-03-27 Scott Graham B. I. Pulsed-multiline excitation for color-blind fluorescence detection
US20040009487A1 (en) * 2001-08-31 2004-01-15 Kadushin James M. Methods for blocking nonspecific hybridizations of nucleic acid sequences
US20040014096A1 (en) * 2002-04-12 2004-01-22 Stratagene Dual-labeled nucleotides
US20040029115A9 (en) * 1990-12-06 2004-02-12 Affymax Technologies, N.V. Sequencing of surface immobilized polymers utilizing microfluorescence detection
US20040038206A1 (en) * 2001-03-14 2004-02-26 Jia Zhang Method for high throughput assay of genetic analysis
US20040054162A1 (en) * 2001-10-30 2004-03-18 Hanna Michelle M. Molecular detection systems utilizing reiterative oligonucleotide synthesis
US20060019276A1 (en) * 2004-05-25 2006-01-26 Timothy Harris Methods and devices for nucleic acid sequence determination

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS5941169B2 (en) 1975-12-25 1984-10-05 シチズン時計株式会社 Elastomer
US4153855A (en) 1977-12-16 1979-05-08 The United States Of America As Represented By The Secretary Of The Army Method of making a plate having a pattern of microchannels
US4351760A (en) 1979-09-07 1982-09-28 Syva Company Novel alkyl substituted fluorescent compounds and polyamino acid conjugates
US4344064A (en) 1979-12-06 1982-08-10 Western Electric Co., Inc. Article carrying a distinctive mark
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5260433A (en) 1982-06-23 1993-11-09 Enzo Diagnostics, Inc. Saccharide specific binding system labeled nucleotides
US4707237A (en) 1982-09-09 1987-11-17 Ciba Corning Diagnostics Corp. System for identification of cells by electrophoresis
USRE34069E (en) 1983-08-18 1992-09-15 Biosyntech Gmbh Process for the preparation of oligonucleotides
US5360523A (en) 1984-03-29 1994-11-01 Li-Cor, Inc. DNA sequencing
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4865968A (en) 1985-04-01 1989-09-12 The Salk Institute For Biological Studies DNA sequencing
US4863849A (en) 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US5242797A (en) 1986-03-21 1993-09-07 Myron J. Block Nucleic acid assay method
CA1340806C (en) 1986-07-02 1999-11-02 James Merrill Prober Method, system and reagents for dna sequencing
US5242796A (en) 1986-07-02 1993-09-07 E. I. Du Pont De Nemours And Company Method, system and reagents for DNA sequencing
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4942124A (en) 1987-08-11 1990-07-17 President And Fellows Of Harvard College Multiplex sequencing
US4793705A (en) 1987-10-07 1988-12-27 The United States Of America As Represented By The United States Department Of Energy Single molecule tracking
US4962037A (en) 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
US4971903A (en) 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
US4979824A (en) 1989-05-26 1990-12-25 Board Of Trustees Of The Leland Stanford Junior University High sensitivity fluorescent single particle and single molecule detection apparatus and method
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE110142T1 (en) 1989-06-14 1994-09-15 Westonbridge Int Ltd MICROPUMP.
US5112736A (en) 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
CA2028261C (en) 1989-10-28 1995-01-17 Won Suck Yang Non-invasive method and apparatus for measuring blood glucose concentration
KR910012538A (en) 1989-12-27 1991-08-08 야마무라 가쯔미 Micro pump and its manufacturing method
DE4006152A1 (en) 1990-02-27 1991-08-29 Fraunhofer Ges Forschung MICROMINIATURIZED PUMP
SE470347B (en) 1990-05-10 1994-01-31 Pharmacia Lkb Biotech Microstructure for fluid flow systems and process for manufacturing such a system
DE69106240T2 (en) 1990-07-02 1995-05-11 Seiko Epson Corp Micropump and method of making a micropump.
US5529679A (en) 1992-02-28 1996-06-25 Hitachi, Ltd. DNA detector and DNA detection method
US5518900A (en) 1993-01-15 1996-05-21 Molecular Tool, Inc. Method for generating single-stranded DNA molecules
US5762876A (en) 1991-03-05 1998-06-09 Molecular Tool, Inc. Automatic genotype determination
US5167784A (en) 1991-09-04 1992-12-01 Xerox Corporation Sequencing large nucleic acid fragments
DE4135655A1 (en) 1991-09-11 1993-03-18 Fraunhofer Ges Forschung MICROMINIATURIZED, ELECTROSTATICALLY OPERATED DIAPHRAGM PUMP
US5265327A (en) 1991-09-13 1993-11-30 Faris Sadeg M Microchannel plate technology
US5405747A (en) 1991-09-25 1995-04-11 The Regents Of The University Of California Office Of Technology Transfer Method for rapid base sequencing in DNA and RNA with two base labeling
US5756285A (en) 1991-09-27 1998-05-26 Amersham Life Science, Inc. DNA cycle sequencing
US5674679A (en) 1991-09-27 1997-10-07 Amersham Life Science, Inc. DNA cycle sequencing
US5632957A (en) 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
US5209834A (en) 1992-03-09 1993-05-11 The United States Of America As Represented By The United States Department Of Energy Ordered transport and identification of particles
DE4220077A1 (en) 1992-06-19 1993-12-23 Bosch Gmbh Robert Micro-pump for delivery of gases - uses working chamber warmed by heating element and controlled by silicon wafer valves.
JPH0622798A (en) 1992-07-07 1994-02-01 Hitachi Ltd Method for determining base sequence
US5403709A (en) 1992-10-06 1995-04-04 Hybridon, Inc. Method for sequencing synthetic oligonucleotides containing non-phosphodiester internucleotide linkages
AU671820B2 (en) 1993-02-10 1996-09-12 Promega Corporation Non-radioactive DNA sequencing
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
US5547859A (en) 1993-08-02 1996-08-20 Goodman; Myron F. Chain-terminating nucleotides for DNA sequencing methods
US5659171A (en) 1993-09-22 1997-08-19 Northrop Grumman Corporation Micro-miniature diaphragm pump for the low pressure pumping of gases
CH689836A5 (en) 1994-01-14 1999-12-15 Westonbridge Int Ltd Micropump.
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
EP0749497B1 (en) 1994-03-08 2000-09-06 Amersham Pharmacia Biotech UK Limited Modifying nucleotide analogues
US5763594A (en) 1994-09-02 1998-06-09 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5514256A (en) 1994-10-28 1996-05-07 Battelle Memorial Institute Apparatus for improved DNA sequencing
US5556790A (en) 1994-12-05 1996-09-17 Pettit; John W. Method for Automated DNA sequencing
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5675155A (en) 1995-04-26 1997-10-07 Beckman Instruments, Inc. Multicapillary fluorescent detection system
US5776767A (en) 1995-12-12 1998-07-07 Visible Genetics Inc. Virtual DNA sequencer
EP0866868B1 (en) 1995-12-15 2001-07-11 Amersham Life Science Inc Thermostable dna polymerase from thermoanaerobacter thermohydrosulfuricus and mutant enzymes thereof with exonuclease activity removed
US6300070B1 (en) * 1999-06-04 2001-10-09 Mosaic Technologies, Inc. Solid phase methods for amplifying multiple nucleic acids
CA2399733C (en) * 2000-02-07 2011-09-20 Illumina, Inc. Nucleic acid detection methods using universal priming
AR031640A1 (en) * 2000-12-08 2003-09-24 Applied Research Systems ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS IN A SOLID SUPPORT

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198540A (en) * 1982-10-28 1993-03-30 Hubert Koster Process for the preparation of oligonucleotides in solution
US4994373A (en) * 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US4725677A (en) * 1983-08-18 1988-02-16 Biosyntech Gmbh Process for the preparation of oligonucleotides
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4811218A (en) * 1986-06-02 1989-03-07 Applied Biosystems, Inc. Real time scanning electrophoresis apparatus for DNA sequencing
US4994372A (en) * 1987-01-14 1991-02-19 President And Fellows Of Harvard College DNA sequencing
US6018041A (en) * 1987-04-01 2000-01-25 Hyseq, Inc. Method of sequencing genomes by hybridization of oligonucleotide probes
US5492806A (en) * 1987-04-01 1996-02-20 Hyseq, Inc. Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes
US4994368A (en) * 1987-07-23 1991-02-19 Syntex (U.S.A.) Inc. Amplification method for polynucleotide assays
US5085562A (en) * 1989-04-11 1992-02-04 Westonbridge International Limited Micropump having a constant output
US6197506B1 (en) * 1989-06-07 2001-03-06 Affymetrix, Inc. Method of detecting nucleic acids
US6346413B1 (en) * 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US5889165A (en) * 1989-06-07 1999-03-30 Affymetrix, Inc. Photolabile nucleoside protecting groups
US6355432B1 (en) * 1989-06-07 2002-03-12 Affymetrix Lnc. Products for detecting nucleic acids
US5108892A (en) * 1989-08-03 1992-04-28 Promega Corporation Method of using a taq dna polymerase without 5'-3'-exonuclease activity
US5096554A (en) * 1989-08-07 1992-03-17 Applied Biosystems, Inc. Nucleic acid fractionation by counter-migration capillary electrophoresis
US5302509A (en) * 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5091652A (en) * 1990-01-12 1992-02-25 The Regents Of The University Of California Laser excited confocal microscope fluorescence scanner and method
US5484701A (en) * 1990-01-26 1996-01-16 E. I. Du Pont De Nemours And Company Method for sequencing DNA using biotin-strepavidin conjugates to facilitate the purification of primer extension products
US5096388A (en) * 1990-03-22 1992-03-17 The Charles Stark Draper Laboratory, Inc. Microfabricated pump
US20040029115A9 (en) * 1990-12-06 2004-02-12 Affymax Technologies, N.V. Sequencing of surface immobilized polymers utilizing microfluorescence detection
US20030044779A1 (en) * 1991-03-05 2003-03-06 Philip Goelet Nucleic acid typing by polymerase extension of oligonucleotides using terminator mixtures
US20030044778A1 (en) * 1991-03-05 2003-03-06 Philip Goelet Nucleic acid typing by polymerase extension of oligonucleotides using terminator mixtures
US20030054361A1 (en) * 1991-11-07 2003-03-20 Nanogen, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
US5304487A (en) * 1992-05-01 1994-04-19 Trustees Of The University Of Pennsylvania Fluid handling in mesoscale analytical devices
US5306403A (en) * 1992-08-24 1994-04-26 Martin Marietta Energy Systems, Inc. Raman-based system for DNA sequencing-mapping and other separations
US20020012910A1 (en) * 1993-10-22 2002-01-31 Robert B. Weiss Automated hybridization/imaging device for fluorescent multiplex dna sequencing
US5610287A (en) * 1993-12-06 1997-03-11 Molecular Tool, Inc. Method for immobilizing nucleic acid molecules
US6028190A (en) * 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6026136A (en) * 1994-08-16 2000-02-15 Radkowsky Thorium Power Corp. Seed-blanket reactors
US5872244A (en) * 1994-09-02 1999-02-16 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US6506560B1 (en) * 1994-09-30 2003-01-14 Invitrogen Corporation Cloned DNA polymerases from Thermotoga and mutants thereof
US5863722A (en) * 1994-10-13 1999-01-26 Lynx Therapeutics, Inc. Method of sorting polynucleotides
US5707506A (en) * 1994-10-28 1998-01-13 Battelle Memorial Institute Channel plate for DNA sequencing
US5710628A (en) * 1994-12-12 1998-01-20 Visible Genetics Inc. Automated electrophoresis and fluorescence detection apparatus and method
US5599695A (en) * 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5876187A (en) * 1995-03-09 1999-03-02 University Of Washington Micropumps with fixed valves
US20030044816A1 (en) * 1995-03-17 2003-03-06 Denison Timothy J. Characterization of individual polymer molecules based on monomer-interface interactions
US6015714A (en) * 1995-03-17 2000-01-18 The United States Of America As Represented By The Secretary Of Commerce Characterization of individual polymer molecules based on monomer-interface interactions
US5712476A (en) * 1995-05-30 1998-01-27 Visible Genetics Inc. Electrophoresis and fluorescence detection apparatus
US5885813A (en) * 1995-05-31 1999-03-23 Amersham Life Science, Inc. Thermostable DNA polymerases
US5861287A (en) * 1995-06-23 1999-01-19 Baylor College Of Medicine Alternative dye-labeled primers for automated DNA sequencing
US6043080A (en) * 1995-06-29 2000-03-28 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6197595B1 (en) * 1995-06-29 2001-03-06 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5733729A (en) * 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US6337185B1 (en) * 1995-11-16 2002-01-08 Amersham Pharmacia Biotech Ab Method of sequencing
US5705018A (en) * 1995-12-13 1998-01-06 Hartley; Frank T. Micromachined peristaltic pump
US6177249B1 (en) * 1995-12-18 2001-01-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
US6361937B1 (en) * 1996-03-19 2002-03-26 Affymetrix, Incorporated Computer-aided nucleic acid sequencing
US6207381B1 (en) * 1996-04-04 2001-03-27 Biacore Ab Method for nucleic acid analysis
US20030003498A1 (en) * 1996-04-18 2003-01-02 Digby Thomas J. Method, apparatus and kits for sequencing of nucleic acids using multiple dyes
US6207960B1 (en) * 1996-05-16 2001-03-27 Affymetrix, Inc System and methods for detection of labeled materials
US6344325B1 (en) * 1996-09-25 2002-02-05 California Institute Of Technology Methods for analysis and sorting of polynucleotides
US6020457A (en) * 1996-09-30 2000-02-01 Dendritech Inc. Disulfide-containing dendritic polymers
US5858671A (en) * 1996-11-01 1999-01-12 The University Of Iowa Research Foundation Iterative and regenerative DNA sequencing method
US6017702A (en) * 1996-12-05 2000-01-25 The Perkin-Elmer Corporation Chain-termination type nucleic acid sequencing method including 2'-deoxyuridine-5'-triphosphate
US5876934A (en) * 1996-12-18 1999-03-02 Pharmacia Biotech Inc. DNA sequencing method
US20020034792A1 (en) * 1996-12-20 2002-03-21 Christian Kilger Method for the uncoupled, direct, exponential amplification and sequencing of dna molecules with the addition of a second thermostable dna polymerase and its application
US6024925A (en) * 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
US6355420B1 (en) * 1997-02-12 2002-03-12 Us Genomics Methods and products for analyzing polymers
US6537757B1 (en) * 1997-03-05 2003-03-25 The Regents Of The University Of Michigan Nucleic acid sequencing and mapping
US6030782A (en) * 1997-03-05 2000-02-29 Orchid Biocomputer, Inc. Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds
US20030060431A1 (en) * 1997-07-31 2003-03-27 Nycomed Amersham Plc Base analogues
US5882904A (en) * 1997-08-04 1999-03-16 Amersham Pharmacia Biotech Inc. Thermococcus barossii DNA polymerase mutants
US6346379B1 (en) * 1997-09-11 2002-02-12 F. Hoffman-La Roche Ag Thermostable DNA polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes
US6511803B1 (en) * 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6337188B1 (en) * 1997-11-21 2002-01-08 Orchid Biosciences, Inc. De novo or “universal” sequencing array
US6335824B1 (en) * 1998-03-20 2002-01-01 Genetic Microsystems, Inc. Wide field of view and high speed scanning microscopy
US20030036080A1 (en) * 1998-08-11 2003-02-20 Caliper Technologies Corp. DNA sequencing using multiple flourescent labels being distinguishable by their decay times
US20020009744A1 (en) * 1998-08-18 2002-01-24 Valery Bogdanov In-line complete spectral fluorescent imaging of nucleic acid molecules
US6524829B1 (en) * 1998-09-30 2003-02-25 Molecular Machines & Industries Gmbh Method for DNA- or RNA-sequencing
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US6514706B1 (en) * 1998-10-26 2003-02-04 Christoph Von Kalle Linear amplification mediated PCR (LAM PCR)
US20020032320A1 (en) * 1998-12-18 2002-03-14 The Texas A&M University System Methods of labelling biomolecules with fluorescent dyes
US6361671B1 (en) * 1999-01-11 2002-03-26 The Regents Of The University Of California Microfabricated capillary electrophoresis chip and method for simultaneously detecting multiple redox labels
US6537755B1 (en) * 1999-03-25 2003-03-25 Radoje T. Drmanac Solution-based methods and materials for sequence analysis by hybridization
US6528288B2 (en) * 1999-04-21 2003-03-04 Genome Technologies, Llc Shot-gun sequencing and amplification without cloning
US6521428B1 (en) * 1999-04-21 2003-02-18 Genome Technologies, Llc Shot-gun sequencing and amplification without cloning
US20030044781A1 (en) * 1999-05-19 2003-03-06 Jonas Korlach Method for sequencing nucleic acid molecules
US20020025529A1 (en) * 1999-06-28 2002-02-28 Stephen Quake Methods and apparatus for analyzing polynucleotide sequences
US20050014175A1 (en) * 1999-06-28 2005-01-20 California Institute Of Technology Methods and apparatuses for analyzing polynucleotide sequences
US6528258B1 (en) * 1999-09-03 2003-03-04 Lifebeam Technologies, Inc. Nucleic acid sequencing using an optically labeled pore
US20020015961A1 (en) * 1999-10-05 2002-02-07 Marek Kwiatkowski Compounds for protecting hydroxyls and methods for their use
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
US20030039738A1 (en) * 2000-06-26 2003-02-27 Cheuk Wai Lun Pet food composition and method
US20030017461A1 (en) * 2000-07-11 2003-01-23 Aclara Biosciences, Inc. Tag cleavage for detection of nucleic acids
US20030054181A1 (en) * 2001-01-12 2003-03-20 Harold Swerdlow Substrate for fluorescence analysis
US20040038206A1 (en) * 2001-03-14 2004-02-26 Jia Zhang Method for high throughput assay of genetic analysis
US20030027140A1 (en) * 2001-03-30 2003-02-06 Jingyue Ju High-fidelity DNA sequencing using solid phase capturable dideoxynucleotides and mass spectrometry
US20030003272A1 (en) * 2001-06-21 2003-01-02 Bruno Laguitton Polyanion/polycation multilayer film for DNA immobilization
US20030008285A1 (en) * 2001-06-29 2003-01-09 Fischer Steven M. Method of DNA sequencing using cleavable tags
US20030008413A1 (en) * 2001-07-02 2003-01-09 Namyong Kim Methods of making and using substrate surfaces having covalently bound polyelectrolyte films
US20030058440A1 (en) * 2001-08-28 2003-03-27 Scott Graham B. I. Pulsed-multiline excitation for color-blind fluorescence detection
US20040009487A1 (en) * 2001-08-31 2004-01-15 Kadushin James M. Methods for blocking nonspecific hybridizations of nucleic acid sequences
US20030059778A1 (en) * 2001-09-24 2003-03-27 Andrew Berlin Nucleic acid sequencing by Raman monitoring of uptake of precursors during molecular replication
US20030058799A1 (en) * 2001-09-24 2003-03-27 Mineo Yamakawa Nucleic acid sequencing by raman monitoring of molecular deconstruction
US20040054162A1 (en) * 2001-10-30 2004-03-18 Hanna Michelle M. Molecular detection systems utilizing reiterative oligonucleotide synthesis
US20040014096A1 (en) * 2002-04-12 2004-01-22 Stratagene Dual-labeled nucleotides
US20060019276A1 (en) * 2004-05-25 2006-01-26 Timothy Harris Methods and devices for nucleic acid sequence determination

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004662A1 (en) * 2007-06-18 2009-01-01 Applera Corporation Method and compositions for nucleic acid amplification
WO2008157641A1 (en) * 2007-06-18 2008-12-24 Applera Corporation Method and compositions for nucleic acid amplification
US20090156412A1 (en) * 2007-12-17 2009-06-18 Helicos Biosciences Corporation Surface-capture of target nucleic acids
EP3023788A1 (en) 2010-05-14 2016-05-25 The General Hospital Corporation Compositions of tumor specific neoantigens
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
EP3699266A1 (en) 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
EP4026912A1 (en) 2012-05-10 2022-07-13 The General Hospital Corporation Methods for determining a nucleotide sequence
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11834718B2 (en) 2013-11-25 2023-12-05 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
DE202014010421U1 (en) 2013-12-17 2015-11-12 Kymab Limited Human goals
DE202014010499U1 (en) 2013-12-17 2015-10-20 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
US11452768B2 (en) 2013-12-20 2022-09-27 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP4219744A2 (en) 2014-01-27 2023-08-02 The General Hospital Corporation Methods of preparing nucleic acids for sequencing
DE202015008988U1 (en) 2014-07-15 2016-06-30 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015009006U1 (en) 2014-07-15 2016-08-19 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015008974U1 (en) 2014-07-15 2016-06-30 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015009002U1 (en) 2014-07-15 2016-08-18 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
DE202015009007U1 (en) 2014-07-15 2016-08-19 Kymab Limited Targeting of human PCSK9 for cholesterol treatment
EP2975059A1 (en) 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
WO2016008899A1 (en) 2014-07-15 2016-01-21 Kymab Limited Targeting human pcsk9 for cholesterol treatment
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
US11719607B2 (en) 2014-09-17 2023-08-08 Hologic, Inc. Method of partial lysis and assay
US9810610B2 (en) 2014-09-17 2017-11-07 Hologic, Inc. Method of partial lysis and assay
US10859475B2 (en) 2014-09-17 2020-12-08 Hologic, Inc. Method of partial lysis and assay
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
EP4299136A2 (en) 2015-12-16 2024-01-03 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
US11183286B2 (en) 2015-12-16 2021-11-23 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
EP3933039A1 (en) 2016-09-15 2022-01-05 ArcherDX, LLC Methods of nucleic acid sample preparation
US10683531B2 (en) 2016-09-15 2020-06-16 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free DNA
US11795492B2 (en) 2016-09-15 2023-10-24 ArcherDX, LLC. Methods of nucleic acid sample preparation
WO2018053362A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation
US11390905B2 (en) 2016-09-15 2022-07-19 Archerdx, Llc Methods of nucleic acid sample preparation for analysis of DNA
US10704082B2 (en) 2016-09-15 2020-07-07 ArcherDX, Inc. Methods of nucleic acid sample preparation
US10947582B2 (en) 2016-11-02 2021-03-16 Archerdx, Llc Methods of nucleic acid sample preparation for immune repertoire sequencing
EP4198140A1 (en) 2016-11-02 2023-06-21 ArcherDX, LLC Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018085599A2 (en) 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2018098362A1 (en) 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11504421B2 (en) 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
US11510973B2 (en) 2017-05-08 2022-11-29 Gritstone Bio, Inc. Alphavirus antigen vectors
WO2019023924A1 (en) 2017-08-01 2019-02-07 Helitec Limited Methods of enriching and determining target nucleotide sequences
US11326202B2 (en) 2017-08-01 2022-05-10 Helitec Limited Methods of enriching and determining target nucleotide sequences
US11264117B2 (en) 2017-10-10 2022-03-01 Gritstone Bio, Inc. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11591619B2 (en) 2019-05-30 2023-02-28 Gritstone Bio, Inc. Modified adenoviruses
US11771747B2 (en) 2020-08-06 2023-10-03 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022204321A1 (en) 2021-03-24 2022-09-29 Ambry Genetics Corporation Conservative concurrent evaluation of dna modifications
WO2023004344A1 (en) 2021-07-20 2023-01-26 Regeneron Pharmaceuticals, Inc. Butyrophilin-like 2 for treating inflammatory disorders

Also Published As

Publication number Publication date
US7220549B2 (en) 2007-05-22
US20060147942A1 (en) 2006-07-06
US20080085840A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
US7220549B2 (en) Stabilizing a nucleic acid for nucleic acid sequencing
US20080032307A1 (en) Use of Single-Stranded Nucleic Acid Binding Proteins In Sequencing
US9868978B2 (en) Single molecule sequencing of captured nucleic acids
US20060024711A1 (en) Methods for nucleic acid amplification and sequence determination
US8367377B2 (en) Methods and devices for nucleic acid sequence determination
US9758825B2 (en) Centroid markers for image analysis of high density clusters in complex polynucleotide sequencing
US20070031875A1 (en) Signal pattern compositions and methods
JP2004531205A (en) Solid support assay systems and methods using non-standard bases
EP1182267B1 (en) Method of determining base sequence of single nucleic acid molecule
US20050239085A1 (en) Methods for nucleic acid sequence determination
US20060118754A1 (en) Stabilizing a polyelectrolyte multilayer
US20060263790A1 (en) Methods for improving fidelity in a nucleic acid synthesis reaction
US20070254280A1 (en) Method of Identifying Characteristic of Molecules

Legal Events

Date Code Title Description
AS Assignment

Owner name: HELICOS BIOSCIENCES CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BUZBY, PHILIP R.;REEL/FRAME:019878/0101

Effective date: 20070919

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: COMPLETE GENOMICS, INC., CALIFORNIA

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0686

Effective date: 20130628

Owner name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC., CALIFORNI

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0598

Effective date: 20130628

Owner name: ILLUMINA, INC., CALIFORNIA

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0783

Effective date: 20130628

Owner name: FLUIDIGM CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HELICOS BIOSCIENCES CORPORATION;REEL/FRAME:030714/0546

Effective date: 20130628

Owner name: SEQLL, LLC, MASSACHUSETTS

Free format text: LICENSE;ASSIGNOR:FLUIDIGM CORPORATION;REEL/FRAME:030714/0633

Effective date: 20130628